Gene info: ID 348

Gene: APOE

GENE ID: 348

Synonyms: AD2|APO-E|ApoE4|LDLCQ5|LPG

Description: apolipoprotein E

Gene type: protein-coding

Location: 19q13.32

dbXrefs: Ensembl:ENSG00000130203 MIM:107741 Vega:OTTHUMG00000128901 UniprotKB:P02649

RefSeq: NG_007084.2

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: CD|ND|AD

# Publications: 358

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 6.309e-1 (AD) 2.569e-2 (ND)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg04406254	chr19:45407945	APOE	Promoter	4.028e-4	Alcohol use disorders	26763658
cg21879725	chr19:45412647	APOE	3'UTR	4.214e-4	Alcohol use disorders	26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
CST3	0.926
FXYD1	0.89
SLC9A3R1	0.883
GLUL	0.88
HTRA1	0.878
SNTA1	0.876
ALDH2	0.872
PTN	0.872
NDRG2	0.865
METRN	0.865

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.614
OR4F29	-0.603
CCDC68	-0.401
SYNPO2	-0.368
TYRP1	-0.366
PROKR2	-0.355
TPH2	-0.352
PPM1E	-0.344
OR14I1	-0.342
KCNH5	-0.341

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00062	Human Serum Albumin	BiotechDrug	9048-46-8	Approved	Target
DB01593	Zinc	Small Molecule	7440-66-6	Approved\|Investigational	Target
DB09130	Copper	Small Molecule	7440-50-8	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C049235	11-dehydro-thromboxane B2	APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]	20530721
C049235	11-dehydro-thromboxane B2	Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
C049235	11-dehydro-thromboxane B2	dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
C049235	11-dehydro-thromboxane B2	tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
C084012	1,1-diethyl-2-hydroxy-2-nitrosohydrazine	"APOE gene mutant form results in decreased susceptibility to 1,1-diethyl-2-hydroxy-2-nitrosohydrazine"	11397713
C049325	1,2-dithiol-3-thione	"1,2-dithiol-3-thione results in increased expression of APOE mRNA"	19162173
C046728	2,2'-azobis(2-amidinopropane)	"APOE protein mutant form affects the susceptibility to 2,2'-azobis(2-amidinopropane)"	9568736
C046728	2,2'-azobis(2-amidinopropane)	"APOE protein mutant form results in increased susceptibility to 2,2'-azobis(2-amidinopropane)"	9409251
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of APOE mRNA"	19114083
C425784	2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole	2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole results in increased expression of APOE mRNA	25781201
C009407	2,5,2',5'-tetrachlorobiphenyl	"2,5,2',5'-tetrachlorobiphenyl affects the expression of APOE mRNA"	21703328
C076996	27-hydroxycholesterol	27-hydroxycholesterol results in increased expression of APOE mRNA	28167099
C076996	27-hydroxycholesterol	27-hydroxycholesterol results in increased expression of APOE protein	28167099
C030370	2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone	"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in increased expression of APOE mRNA"	20206263
C023035	3,4,5,3',4'-pentachlorobiphenyl	"3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of APOE mRNA"	23196670
C050224	3,5,5-trimethylhexanoylferrocene	"3,5,5-trimethylhexanoylferrocene results in increased expression of APOE protein"	22649188
C018258	3-deazaadenosine	[3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOE protein	8944747
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOE mRNA"	27188386
C032642	4-aminophenylarsenoxide	4-aminophenylarsenoxide binds to APOE protein	26598702
C032642	4-aminophenylarsenoxide	arsenic trioxide inhibits the reaction [4-aminophenylarsenoxide binds to APOE protein]	26598702
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOE mRNA"	27188386
C115626	8,12-iso-isoprostane F2alpha-VI	"ALOX15 mutant form inhibits the reaction [APOE mutant form results in increased abundance of 8,12-iso-isoprostane F2alpha-VI]"	16303615
C115626	8,12-iso-isoprostane F2alpha-VI	"APOE mutant form results in increased abundance of 8,12-iso-isoprostane F2alpha-VI"	16303615
C115626	8,12-iso-isoprostane F2alpha-VI	"Vitamin E inhibits the reaction [APOE mutant form results in increased abundance of 8,12-iso-isoprostane F2alpha-VI]"	16303615
C075750	8-epi-prostaglandin F2alpha	[APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha	17118406
D000074	Acenocoumarol	APOE gene polymorphism affects the susceptibility to Acenocoumarol	15861030
D000082	Acetaminophen	Acetaminophen results in decreased expression of APOE mRNA	29067470
D000082	Acetaminophen	Acetaminophen results in increased expression of APOE mRNA	23358195
D000082	Acetaminophen	Acetaminophen affects the expression of APOE protein	16099942
D000082	Acetaminophen	Acetaminophen results in decreased expression of APOE protein	16687475
D000109	Acetylcholine	APOE gene mutant form results in decreased susceptibility to Acetylcholine	11397713
D000109	Acetylcholine	APOE protein affects the susceptibility to Acetylcholine	17899169
D000171	Acrolein	Acrolein affects the folding of APOE protein	17580963
D000171	Acrolein	Acrolein results in decreased activity of APOE protein	17580963
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of APOE protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of APOE mRNA	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of APOE mRNA	19770486
C096920	AGN 193109	AGN 193109 inhibits the reaction [Tretinoin results in increased expression of APOE mRNA]	16505366
D000517	alpha-Chlorohydrin	alpha-Chlorohydrin analog results in increased expression of APOE protein	26597043
D013196	Dihydrotestosterone	APOE gene polymorphism affects the reaction [Dihydrotestosterone affects the phosphorylation of MAPK10 protein]	17395708
D013196	Dihydrotestosterone	APOE gene polymorphism affects the reaction [Dihydrotestosterone affects the phosphorylation of MAPK9 protein]	17395708
D013196	Dihydrotestosterone	APOE gene polymorphism affects the susceptibility to Dihydrotestosterone	17395708
C061621	alpha-naphthyl isocyanate	alpha-naphthyl isocyanate affects the expression of APOE protein	16099942
D024502	alpha-Tocopherol	alpha-Tocopherol deficiency results in increased expression of APOE mRNA	24657723
D019856	Ethanolamine	[3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOE protein	8944747
D019856	Ethanolamine	[Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOE protein	8944747
D019856	Ethanolamine	[Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOE protein	8944747
D000638	Amiodarone	Amiodarone results in decreased expression of APOE mRNA	17991464
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of APOE mRNA	16483693
D000975	Antioxidants	APOE gene mutant form results in decreased abundance of Antioxidants	25037058
D000975	Antioxidants	Enalapril inhibits the reaction [APOE gene mutant form results in decreased abundance of Antioxidants]	25037058
D000975	Antioxidants	paricalcitol inhibits the reaction [APOE gene mutant form results in decreased abundance of Antioxidants]	25037058
D016718	Arachidonic Acid	APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]	20530721
D016718	Arachidonic Acid	Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
D016718	Arachidonic Acid	dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
D016718	Arachidonic Acid	tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
D016718	Arachidonic Acid	APOE gene mutant form results in decreased susceptibility to Arachidonic Acid	20530721
D016718	Arachidonic Acid	Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]	20530721
D016718	Arachidonic Acid	dazoxiben inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]	20530721
D016718	Arachidonic Acid	Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]	20530721
D016718	Arachidonic Acid	tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]	20530721
D001151	Arsenic	APOE polymorphism results in increased susceptibility to Arsenic	18022660
D001151	Arsenic	APOE gene mutant form results in increased susceptibility to Arsenic	22956628
D001151	Arsenic	APOE protein affects the susceptibility to Arsenic	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which affects the expression of AQP1 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which affects the expression of CDCA5 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which affects the expression of CYP7A1 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which affects the expression of GSTA4 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which affects the expression of LEF1 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which affects the expression of NUBP1 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which affects the expression of UGDH mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR10A mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR149 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR15B mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR184 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR188 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR193A mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR211 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR222 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR337 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR376A mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR412 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR467B mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR497 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR592 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR679 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR681 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIR719 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in decreased expression of MIRLET7D mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of HSPA1B mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of HSPA1B protein	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of HSPA8 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of MIR211 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of MIR294 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of MIR361 mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of PELO mRNA	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of SREBF1 protein	22719926
D001151	Arsenic	[APOE protein affects the susceptibility to Arsenic] which results in increased expression of TNF mRNA	22719926
D001151	Arsenic	Arsenic results in increased expression of APOE mRNA	24019935
C006632	arsenic trioxide	arsenic trioxide inhibits the reaction [4-aminophenylarsenoxide binds to APOE protein]	26598702
C006632	arsenic trioxide	arsenic trioxide results in decreased expression of APOE mRNA	22521957
D017636	Asbestos, Amphibole	"Asbestos, Amphibole results in increased expression of APOE mRNA"	22352330
D001205	Ascorbic Acid	Ascorbic Acid results in increased expression of APOE mRNA	15372504
D001241	Aspirin	APOE polymorphism affects the susceptibility to Aspirin	15084783
D001241	Aspirin	Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
D001241	Aspirin	Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]	20530721
D000069059	Atorvastatin Calcium	Atorvastatin Calcium results in decreased expression of APOE mRNA	16386711
D000069059	Atorvastatin Calcium	Atorvastatin Calcium results in decreased expression of APOE protein	16386711
D000069059	Atorvastatin Calcium	[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin Calcium co-treated with Valsartan] results in decreased expression of APOE protein	19603250
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of APOE mRNA	19770486
D004958	Estradiol	ESR1 protein promotes the reaction [Estradiol results in decreased expression of APOE mRNA]	25210133
D004958	Estradiol	Estradiol results in decreased expression of APOE mRNA	25210133
D004958	Estradiol	Estradiol results in increased expression of APOE mRNA	19484750
D001629	Bezafibrate	[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin Calcium co-treated with Valsartan] results in decreased expression of APOE protein	19603250
D001629	Bezafibrate	Bezafibrate results in increased expression of APOE protein	8017468
D001629	Bezafibrate	[Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOE protein	8944747
D001629	Bezafibrate	Bezafibrate results in decreased expression of APOE protein	9006809
C099952	bifenthrin	bifenthrin results in increased expression of APOE mRNA	26071804
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of APOE mRNA	27685785
C065545	bismuth nitrate	bismuth nitrate results in increased expression of APOE protein	1883846
C006780	bisphenol A	bisphenol A results in increased expression of APOE mRNA	28159858
C006780	bisphenol A	bisphenol A results in decreased expression of APOE mRNA	27183338
C006780	bisphenol A	bisphenol A results in increased expression of APOE mRNA	27685785
C006780	bisphenol A	bisphenol A affects the methylation of APOE promoter	27334623
C006780	bisphenol A	bisphenol A affects the expression of APOE mRNA	25181051
C053342	brevetoxin	brevetoxin analog results in decreased expression of APOE mRNA	14529743
C013418	bromfenacoum	bromfenacoum results in increased expression of APOE protein	28903499
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in increased expression of APOE mRNA	15336504
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide affects the localization of APOE protein	19720132
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in increased expression of APOE mRNA	19720132
C584509	C646 compound	C646 compound affects the expression of APOE mRNA	26191083
D002101	Cacodylic Acid	APOE protein affects the susceptibility to Cacodylic Acid	28728140
D002101	Cacodylic Acid	AS3MT protein affects the reaction [APOE protein affects the susceptibility to Cacodylic Acid]	28728140
D002104	Cadmium	APOE protein binds to Cadmium	23896426
D002104	Cadmium	APOE gene mutant form results in increased susceptibility to Cadmium	21799275
D002104	Cadmium	[APOE gene mutant form results in increased susceptibility to Cadmium] which results in increased expression of HSPD1	21799275
D002104	Cadmium	[APOE gene mutant form results in increased susceptibility to Cadmium] which results in increased expression of VCAM1	21799275
D002104	Cadmium	Cadmium results in decreased expression of APOE mRNA	28315714
D002104	Cadmium	Cadmium results in decreased expression of APOE protein	28315714
D002104	Cadmium	decitabine inhibits the reaction [Cadmium results in decreased expression of APOE mRNA]	28315714
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of APOE mRNA	18804290
D000001	Calcimycin	APOE gene mutant form results in decreased susceptibility to Calcimycin	11397713
D002118	Calcium	APOE protein affects the abundance of Calcium	17899169
D002118	Calcium	Calcium affects the expression of APOE mRNA	15913539
D002211	Capsaicin	APOE affects the reaction [Capsaicin results in decreased expression of LRP1 protein]	21908651
D002211	Capsaicin	APOE affects the reaction [Capsaicin results in increased expression of ABCA1 protein]	21908651
D002211	Capsaicin	Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]	21908651
D002211	Capsaicin	Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Triglycerides]	21908651
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of APOE protein	16845489
D002392	Catechin	Catechin inhibits the reaction [APOE gene mutant form results in increased expression of EDN1 protein]	20093625
C026690	cerous chloride	cerous chloride affects the expression of APOE mRNA	28954213
C026690	cerous chloride	[cerous chloride co-treated with lanthanum chloride] results in increased expression of APOE mRNA	28954213
D017332	Cetirizine	APOE gene mutant form inhibits the reaction [Cetirizine results in decreased expression of MLXIPL mRNA]	24852568
D017332	Cetirizine	APOE protein results in decreased susceptibility to [Dietary Fats co-treated with Cetirizine]	24852568
D017332	Cetirizine	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CCL23 protein	25020133
D017332	Cetirizine	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CKM protein	25020133
D017332	Cetirizine	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CXCL1 protein	25020133
D017332	Cetirizine	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS2 mRNA	25020133
D017332	Cetirizine	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS3 mRNA	25020133
D017332	Cetirizine	Cetirizine results in decreased expression of APOE mRNA	24852568
C062876	cetrorelix	[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of APOE mRNA	18160741
C062876	cetrorelix	[cetrorelix co-treated with testosterone enanthate] results in decreased expression of APOE mRNA	18160741
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in increased expression of APOE mRNA	25270620
C100187	chloropicrin	chloropicrin results in decreased expression of APOE mRNA	26352163
D002738	Chloroquine	Chloroquine affects the localization of APOE protein	8616629
D002784	Cholesterol	[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol	21908651
D002784	Cholesterol	APOE gene mutant form promotes the reaction [Dietary Fats results in increased abundance of Cholesterol]	11397713
D002784	Cholesterol	APOE gene mutant form results in increased abundance of Cholesterol	24933211\|2503705
D002784	Cholesterol	"APOE inhibits the reaction [Cholesterol, Dietary results in increased abundance of Cholesterol]"	12472773
D002784	Cholesterol	APOE protein affects the susceptibility to Cholesterol	16179587
D002784	Cholesterol	APOE protein results in increased export of Cholesterol	22022523
D002784	Cholesterol	Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]	21908651
D002784	Cholesterol	CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein]	21169230
D002784	Cholesterol	Cholesterol affects the localization of APOE protein	21169230
D002784	Cholesterol	Enalapril inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]	25037058
D002784	Cholesterol	methyl-beta-cyclodextrin inhibits the reaction [Cholesterol affects the localization of APOE protein]	21169230
D002784	Cholesterol	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]	24933211
D002784	Cholesterol	paricalcitol inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]	25037058
D002784	Cholesterol	Cholesterol affects the localization of APOE protein	21169230
D002784	Cholesterol	Cholesterol promotes the reaction [APOE protein binds to CAV1 protein]	21169230
D002791	Cholesterol, Dietary	"[Fructose co-treated with Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of APOE mRNA"	19509184
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which affects the activity of and affects the localization of NFKB1 protein"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which affects the activity of and affects the localization of RELA protein"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of CCL2 mRNA"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of CCL2 protein"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of NCF1 mRNA"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of NCF1 protein"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of RAC1 mRNA"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of RAC1 protein"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of TNF mRNA"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of TNF protein"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of VCAM1 mRNA"	18287887
D002791	Cholesterol, Dietary	"[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of VCAM1 protein"	18287887
D002791	Cholesterol, Dietary	"APOE inhibits the reaction [Cholesterol, Dietary results in increased abundance of Cholesterol]"	12472773
D002791	Cholesterol, Dietary	"APOE protein affects the susceptibility to Cholesterol, Dietary"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which affects the activity of and affects the localization of NFKB1 protein]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which affects the activity of and affects the localization of RELA protein]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of CCL2 mRNA]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of CCL2 protein]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of NCF1 mRNA]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of NCF1 protein]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of RAC1 mRNA]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of RAC1 protein]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of TNF mRNA]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of TNF protein]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of VCAM1 mRNA]"	18287887
D002791	Cholesterol, Dietary	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of VCAM1 protein]"	18287887
D008076	Cholesterol, HDL	"APOE gene polymorphism affects the abundance of Cholesterol, HDL"	16030523
D008076	Cholesterol, HDL	"APOE gene polymorphism results in increased abundance of Cholesterol, HDL"	17289397
D008076	Cholesterol, HDL	"[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased abundance of Cholesterol, HDL analog"	17118406
D008078	Cholesterol, LDL	"[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased abundance of Cholesterol, LDL"	17118406
D008078	Cholesterol, LDL	"[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased abundance of Cholesterol, LDL"	25020133
D015243	Cholesterol, VLDL	"[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased abundance of Cholesterol, VLDL"	17118406
D002994	Clofibrate	Clofibrate results in increased expression of APOE mRNA	25270620
D002995	Clofibric Acid	[Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOE protein	8944747
D003035	Cobalt	[tungsten carbide co-treated with Cobalt] results in decreased expression of APOE mRNA	18078969
C052387	cocoa butter	cocoa butter promotes the reaction [APOE gene mutant form results in increased susceptibility to sodium arsenite]	14594625
D003300	Copper	APOE protein binds to Copper	23896426
D003300	Copper	APOE gene mutant form results in increased uptake of Copper	25749341
D003300	Copper	Copper deficiency results in increased expression of APOE mRNA	19821111
D003300	Copper	Copper results in decreased expression of APOE mRNA	22465980
D019327	Copper Sulfate	APOE protein inhibits the reaction [Copper Sulfate results in increased expression of HMOX1 protein]	25749341
D019327	Copper Sulfate	APOE protein inhibits the reaction [Copper Sulfate results in increased expression of NQO1 protein]	25749341
D019327	Copper Sulfate	APOE protein mutant form affects the susceptibility to Copper Sulfate	9568736
D019327	Copper Sulfate	APOE protein mutant form results in increased susceptibility to Copper Sulfate	9409251
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of APOE mRNA	18579281
D003474	Curcumin	Curcumin affects the expression of APOE mRNA	27208389
C057862	cyanoginosin LR	cyanoginosin LR results in increased expression of APOE protein	26984711
D003520	Cyclophosphamide	Cyclophosphamide results in decreased expression of APOE mRNA	15331540
D003520	Cyclophosphamide	Cyclophosphamide results in increased expression of APOE mRNA	21041162
D016572	Cyclosporine	Cyclosporine results in decreased expression of APOE mRNA	20106945\|2556210
C072247	cyclo(Trp-Asp-Pro-Val-Leu)	cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of EDN1 mRNA]	19150882
C072247	cyclo(Trp-Asp-Pro-Val-Leu)	cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of MMP9 mRNA]	19150882
C072247	cyclo(Trp-Asp-Pro-Val-Leu)	cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of MMP9 protein]	19150882
C017160	cypermethrin	cypermethrin results in increased expression of APOE mRNA	21142847
C017160	cypermethrin	cypermethrin results in decreased expression of APOE mRNA	11428908\|9650644
D015853	Cysteine Proteinase Inhibitors	Cysteine Proteinase Inhibitors inhibits the reaction [Penicillins results in increased expression of APOE mRNA]	23266720
D015853	Cysteine Proteinase Inhibitors	Cysteine Proteinase Inhibitors inhibits the reaction [Penicillins results in increased expression of APOE protein]	23266720
D015853	Cysteine Proteinase Inhibitors	Cysteine Proteinase Inhibitors results in decreased expression of APOE mRNA	23266720
C029166	dazoxiben	dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
C029166	dazoxiben	dazoxiben inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]	20530721
C014347	decitabine	decitabine inhibits the reaction [Cadmium results in decreased expression of APOE mRNA]	28315714
D003671	DEET	[Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of APOE mRNA	28659758
D017135	Desogestrel	[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of APOE mRNA	18160741
D064791	Desoxycorticosterone Acetate	"[Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary co-treated with Potassium Chloride] results in increased expression of APOE mRNA"	22228705
D003907	Dexamethasone	Dexamethasone results in increased expression of APOE mRNA	25047013
D003907	Dexamethasone	Dexamethasone results in increased expression of APOE mRNA	21041162
D003976	Diazinon	Diazinon affects the expression of APOE mRNA	22546817
D002945	Cisplatin	APOE protein results in decreased susceptibility to Cisplatin	20430468
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of APOE mRNA	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of APOE mRNA	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of APOE mRNA	24865317
D002945	Cisplatin	Cisplatin results in increased expression of APOE mRNA	21151649
D003633	Dichlorodiphenyl Dichloroethylene	APOE gene polymorphism results in increased susceptibility to Dichlorodiphenyl Dichloroethylene	24473795
D004026	Dieldrin	Dieldrin results in decreased expression of APOE mRNA	20438755
D004026	Dieldrin	Dieldrin results in decreased expression of APOE protein	20584760
D004041	Dietary Fats	"[Fructose co-treated with Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of APOE mRNA"	19509184
D004041	Dietary Fats	APOE affects the susceptibility to Dietary Fats	21908651
D004041	Dietary Fats	[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol	21908651
D004041	Dietary Fats	[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Triglycerides	21908651
D004041	Dietary Fats	[APOE affects the susceptibility to Dietary Fats] which affects the expression of ABCA1 protein	21908651
D004041	Dietary Fats	[APOE affects the susceptibility to Dietary Fats] which affects the expression of LRP1 protein	21908651
D004041	Dietary Fats	APOE gene mutant form affects the susceptibility to Dietary Fats	19891982
D004041	Dietary Fats	APOE gene mutant form promotes the reaction [Dietary Fats results in increased abundance of Cholesterol]	11397713
D004041	Dietary Fats	APOE gene mutant form results in increased susceptibility to Dietary Fats	24017971
D004041	Dietary Fats	APOE protein affects the reaction [Dietary Fats affects the expression of HMOX1 protein]	24017971
D004041	Dietary Fats	APOE protein affects the susceptibility to Dietary Fats	22659316\|2433071
D004041	Dietary Fats	APOE protein affects the susceptibility to [Dietary Fats co-treated with Particulate Matter]	17655762
D004041	Dietary Fats	[APOE protein affects the susceptibility to [Dietary Fats co-treated with Particulate Matter]] which affects the expression of ATF4 mRNA	17655762
D004041	Dietary Fats	[APOE protein affects the susceptibility to [Dietary Fats co-treated with Particulate Matter]] which affects the expression of HMOX1 mRNA	17655762
D004041	Dietary Fats	[APOE protein affects the susceptibility to [Dietary Fats co-treated with Particulate Matter]] which affects the expression of XBP1 mRNA	17655762
D004041	Dietary Fats	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Particulate Matter results in increased expression of HMOX1 mRNA]	24330719
D004041	Dietary Fats	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]	24330719
D004041	Dietary Fats	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Particulate Matter results in increased expression of NQO1 mRNA]	24330719
D004041	Dietary Fats	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Vehicle Emissions results in increased expression of HMOX1 mRNA]	24330719
D004041	Dietary Fats	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Vehicle Emissions results in increased expression of NFE2L2 mRNA]	24330719
D004041	Dietary Fats	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Vehicle Emissions results in increased expression of NQO1 mRNA]	24330719
D004041	Dietary Fats	APOE protein mutant form results in increased susceptibility to Dietary Fats	22869926
D004041	Dietary Fats	APOE protein results in decreased susceptibility to Dietary Fats	24852568
D004041	Dietary Fats	APOE protein results in decreased susceptibility to [Dietary Fats co-treated with Cetirizine]	24852568
D004041	Dietary Fats	APOE protein results in decreased susceptibility to [Dietary Fats co-treated with fexofenadine]	24852568
D004041	Dietary Fats	[AS3MT protein co-treated with APOE protein] affects the susceptibility to Dietary Fats	28728140
D004041	Dietary Fats	Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]	21908651
D004041	Dietary Fats	Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Triglycerides]	21908651
D004041	Dietary Fats	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CCL23 protein	25020133
D004041	Dietary Fats	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CKM protein	25020133
D004041	Dietary Fats	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CXCL1 protein	25020133
D004041	Dietary Fats	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS2 mRNA	25020133
D004041	Dietary Fats	[Cetirizine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS3 mRNA	25020133
D004041	Dietary Fats	Dietary Fats results in decreased expression of APOE mRNA	18042831
D004041	Dietary Fats	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CKM protein	25020133
D004041	Dietary Fats	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of IL1A protein	25020133
D004041	Dietary Fats	"[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased abundance of Cholesterol, LDL"	25020133
D004041	Dietary Fats	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of CCL3 protein	25020133
D004041	Dietary Fats	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS2 mRNA	25020133
D004041	Dietary Fats	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS3 mRNA	25020133
D004041	Dietary Fats	Quercetin inhibits the reaction [APOE gene mutant form results in increased susceptibility to Dietary Fats]	24017971
D004041	Dietary Fats	Tobacco Smoke Pollution promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]	22659316
D004041	Dietary Fats	Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]	19891982
D004041	Dietary Fats	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in decreased expression of MMP13 mRNA	19891982
D004041	Dietary Fats	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in decreased expression of MMP8 mRNA	19891982
D004041	Dietary Fats	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in increased expression of EDN1 mRNA	19891982
D004041	Dietary Fats	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in increased expression of MMP9 mRNA	19891982
D004041	Dietary Fats	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in increased expression of TIMP2 mRNA	19891982
D004051	Diethylhexyl Phthalate	APOE gene mutant form results in increased susceptibility to Diethylhexyl Phthalate	25270622
D004051	Diethylhexyl Phthalate	[APOE gene mutant form results in increased susceptibility to Diethylhexyl Phthalate] which results in decreased expression of ABCG5 protein	25270622
D004051	Diethylhexyl Phthalate	[APOE gene mutant form results in increased susceptibility to Diethylhexyl Phthalate] which results in decreased expression of ABCG8 protein	25270622
D004051	Diethylhexyl Phthalate	[APOE gene mutant form results in increased susceptibility to Diethylhexyl Phthalate] which results in decreased expression of CYP7A1 protein	25270622
D004051	Diethylhexyl Phthalate	[APOE gene mutant form results in increased susceptibility to Diethylhexyl Phthalate] which results in decreased expression of LDLR protein	25270622
D004051	Diethylhexyl Phthalate	[APOE gene mutant form results in increased susceptibility to Diethylhexyl Phthalate] which results in decreased expression of NR1H3 protein	25270622
D004052	Diethylnitrosamine	[Phenobarbital co-treated with Diethylnitrosamine] results in increased expression of APOE protein	20935162
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of APOE mRNA	15766595
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of APOE mRNA	15171707
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of APOE mRNA	21041162
C472511	dimethylarsinous acid	APOE protein affects the susceptibility to dimethylarsinous acid	28728140
D015127	9,10-Dimethyl-1,2-benzanthracene	"9,10-Dimethyl-1,2-benzanthracene results in increased expression of APOE mRNA"	22485181
D015127	9,10-Dimethyl-1,2-benzanthracene	"9,10-Dimethyl-1,2-benzanthracene affects the expression of APOE mRNA"	21785161
D004176	Dipyridamole	[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin Calcium co-treated with Valsartan] results in decreased expression of APOE protein	19603250
D004237	Diuron	Diuron results in decreased expression of APOE mRNA	21551480\|2515243
D004317	Doxorubicin	Doxorubicin results in increased expression of APOE mRNA	15033991
D004317	Doxorubicin	Doxorubicin results in increased expression of APOE protein	8255516
C070609	EMD 53998	EMD 53998 analog results in decreased expression of APOE mRNA	24977338
D004656	Enalapril	[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin Calcium co-treated with Valsartan] results in decreased expression of APOE protein	19603250
D004656	Enalapril	Enalapril inhibits the reaction [APOE gene mutant form results in decreased abundance of Antioxidants]	25037058
D004656	Enalapril	Enalapril inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]	25037058
C118739	entinostat	entinostat results in increased expression of APOE mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOE mRNA"	27188386
C109476	epoxiconazole	epoxiconazole results in increased expression of APOE mRNA	28454766
D000431	Ethanol	Ethanol results in increased secretion of APOE protein	17478430
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of APOE mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of APOE mRNA	14976129\|1617478
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of APOE mRNA	17942748
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of APOE mRNA	17351261\|1755790
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of APOE mRNA	16174780
D015025	Zearalenone	Zearalenone results in decreased expression of APOE mRNA	19371625
D005228	Fatty Acids, Essential	"Fatty Acids, Essential deficiency results in decreased expression of APOE mRNA"	23333450
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which affects the activity of and affects the localization of NFKB1 protein]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which affects the activity of and affects the localization of RELA protein]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of CCL2 mRNA]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of CCL2 protein]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of NCF1 mRNA]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of NCF1 protein]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of RAC1 mRNA]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of RAC1 protein]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of TNF mRNA]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of TNF protein]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of VCAM1 mRNA]"	18287887
D015736	Felodipine	"Felodipine inhibits the reaction [[APOE gene mutant form affects the susceptibility to Cholesterol, Dietary] which results in increased expression of VCAM1 protein]"	18287887
C093230	fexofenadine	APOE gene mutant form inhibits the reaction [fexofenadine results in decreased expression of MLXIPL mRNA]	24852568
C093230	fexofenadine	APOE protein results in decreased susceptibility to [Dietary Fats co-treated with fexofenadine]	24852568
C093230	fexofenadine	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of CKM protein	25020133
C093230	fexofenadine	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in decreased expression of IL1A protein	25020133
C093230	fexofenadine	"[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased abundance of Cholesterol, LDL"	25020133
C093230	fexofenadine	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of CCL3 protein	25020133
C093230	fexofenadine	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS2 mRNA	25020133
C093230	fexofenadine	[fexofenadine co-treated with Dietary Fats co-treated with APOE gene mutant form] results in increased expression of NOS3 mRNA	25020133
C093230	fexofenadine	fexofenadine results in decreased expression of APOE mRNA	24852568
D005459	Fluorides	Fluorides results in increased expression of APOE protein	25556215
C061365	flusilazole	flusilazole affects the expression of APOE mRNA	22634333
D005485	Flutamide	Flutamide results in increased expression of APOE protein	17311803
C065180	fluvastatin	[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin	19773416
C065180	fluvastatin	fluvastatin results in increased expression of APOE protein	8017468
D005492	Folic Acid	APOE gene mutant form affects the susceptibility to Folic Acid	17118406
D005492	Folic Acid	[APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha	17118406
D005492	Folic Acid	[APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased expression of APOB protein	17118406
D005492	Folic Acid	"[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased abundance of Cholesterol, HDL analog"	17118406
D005492	Folic Acid	"[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased abundance of Cholesterol, LDL"	17118406
D005492	Folic Acid	"[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased abundance of Cholesterol, VLDL"	17118406
D005492	Folic Acid	[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased expression of APOA1 protein	17118406
D005492	Folic Acid	[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased expression of APOA2 protein	17118406
D005492	Folic Acid	[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased expression of APOA4 mRNA	17118406
D005492	Folic Acid	[APOE gene mutant form affects the susceptibility to Folic Acid] which results in increased expression of APOA4 protein	17118406
D005632	Fructose	"[Fructose co-treated with Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of APOE mRNA"	19509184
C039281	furan	furan results in decreased expression of APOE mRNA	26194646
D005688	Galactosamine	Galactosamine results in decreased expression of APOE protein	6631239
D015248	Gemfibrozil	Gemfibrozil results in increased expression of APOE protein	9006809
D019833	Genistein	Genistein results in decreased expression of APOE mRNA	21048042
C100093	gentamicin C	APOE protein inhibits the reaction [gentamicin C results in decreased expression of and results in decreased activity of SLC5A1 protein]	15777622
C100093	gentamicin C	APOE protein inhibits the reaction [gentamicin C results in decreased expression of SLC5A1 mRNA]	15777622
C100093	gentamicin C	APOE protein results in decreased uptake of gentamicin C	15777622
D005944	Glucosamine	INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]	16380481
D005944	Glucosamine	[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine	16380481
D005947	Glucose	Glucose deficiency affects the secretion of APOE protein	24802182
D005978	Glutathione	APOE gene mutant form results in decreased abundance of Glutathione	24933211
D005978	Glutathione	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]	24933211
D006152	Cyclic GMP	APOE gene mutant form results in decreased abundance of Cyclic GMP	11397713
C473027	GW 3965	GW 3965 results in increased expression of APOE mRNA	17449538
C412815	GW 4064	GW 4064 promotes the reaction [NR1H4 protein binds to APOE gene]	20091679
C412815	GW 4064	GW 4064 results in increased expression of APOE mRNA	26655953
C029424	hydrazine	hydrazine results in decreased expression of APOE mRNA	15370871
C029424	hydrazine	hydrazine results in decreased expression of APOE protein	15370871
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the localization of APOE protein	19720132
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased expression of APOE mRNA	19720132
D019161	Hydroxymethylglutaryl-CoA Reductase Inhibitors	APOE gene polymorphism results in increased susceptibility to Hydroxymethylglutaryl-CoA Reductase Inhibitors	17289397
D000960	Hypolipidemic Agents	Hypolipidemic Agents results in decreased expression of APOE protein	19603250
C492448	ICG 001	ICG 001 results in increased expression of APOE mRNA	26191083
C121876	imisopasem manganese	imisopasem manganese inhibits the reaction [APOE gene mutant form results in increased chemical synthesis of Superoxides]	12871831
C121876	imisopasem manganese	imisopasem manganese results in decreased susceptibility to APOE gene mutant form	12871831
C020758	indium trichloride	indium trichloride results in increased expression of APOE protein	19539025
D007213	Indomethacin	Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]	20530721
D007501	Iron	APOE gene polymorphism results in increased susceptibility to Iron	15993987
C088408	ivabradine	APOE affects the susceptibility to ivabradine	21821843
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of APOE mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of APOE mRNA	27392435
C006552	kaempferol	kaempferol inhibits the reaction [APOE affects the expression of CD44 mRNA]	22005275
C006552	kaempferol	kaempferol inhibits the reaction [APOE affects the expression of CD44 protein]	22005275
C006552	kaempferol	kaempferol inhibits the reaction [APOE affects the expression of SPP1 mRNA]	22005275
C006552	kaempferol	kaempferol inhibits the reaction [APOE affects the expression of SPP1 protein]	22005275
D007608	Kainic Acid	Kainic Acid results in decreased expression of APOE mRNA	17997037
D007649	Ketamine	APOE results in decreased susceptibility to Ketamine	9778666
D007649	Ketamine	Ketamine results in increased expression of APOE mRNA	20080153
D007657	Ketone Bodies	Ketone Bodies results in increased expression of APOE mRNA	16807920
D015121	6-Ketoprostaglandin F1 alpha	APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha	14966570
D015121	6-Ketoprostaglandin F1 alpha	nimesulide inhibits the reaction [APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha]	14966570
D064747	Lansoprazole	Lansoprazole results in increased expression of APOE mRNA	20060385
D064747	Lansoprazole	Lansoprazole results in increased expression of APOE protein	20060385
D064747	Lansoprazole	Lansoprazole results in increased expression of APOE protein	20060385
C028521	lanthanum chloride	[cerous chloride co-treated with lanthanum chloride] results in increased expression of APOE mRNA	28954213
C028521	lanthanum chloride	lanthanum chloride results in increased expression of APOE mRNA	28954213
D007854	Lead	Lead affects the expression of APOE protein	20681587
D007854	Lead	APOE gene affects the susceptibility to Lead	20681587
C008261	lead acetate	lead acetate results in increased expression of APOE mRNA	21829687
D054709	Lecithins	[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein	6631239
C442865	lipopolysaccharide, Helicobacter pylori	"lipopolysaccharide, Helicobacter pylori results in increased expression of APOE mRNA"	21220698
D008070	Lipopolysaccharides	Lipopolysaccharides results in decreased expression of APOE mRNA	16847310
D008148	Lovastatin	Lovastatin affects the expression of APOE mRNA	27208389
C097284	manganese(III)-tetrakis(4-benzoic acid)porphyrin	manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [APOE gene mutant form results in increased abundance of Superoxides]	11397713
D008466	Mechlorethamine	Mechlorethamine results in increased expression of APOE mRNA	26273949\|2818490
D008466	Mechlorethamine	Valproic Acid promotes the reaction [Mechlorethamine results in increased expression of APOE mRNA]	28184907
D008628	Mercury	APOE gene polymorphism affects the susceptibility to Mercury	23603214
D008628	Mercury	APOE polymorphism affects the susceptibility to Mercury	12897404
C108732	methyl-beta-cyclodextrin	methyl-beta-cyclodextrin inhibits the reaction [Cholesterol affects the localization of APOE protein]	21169230
C004925	methylmercuric chloride	methylmercuric chloride affects the expression of APOE protein	27012723
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of APOE mRNA	23179753
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium affects the expression of APOE mRNA	12710931
C016599	mono-(2-ethylhexyl)phthalate	mono-(2-ethylhexyl)phthalate results in increased expression of APOE mRNA	22087261
C406082	monomethylarsonous acid	APOE protein affects the susceptibility to monomethylarsonous acid	28728140
C406082	monomethylarsonous acid	AS3MT protein affects the reaction [APOE protein affects the susceptibility to monomethylarsonous acid]	28728140
D009020	Morphine	Morphine deficiency affects the reaction [Morphine results in increased expression of APOE protein]	23056601
D009020	Morphine	Morphine results in increased expression of APOE protein	23056601
C008577	myricitrin	myricitrin inhibits the reaction [APOE gene mutant form results in decreased activity of CAT protein]	23639522
C008577	myricitrin	myricitrin inhibits the reaction [APOE gene mutant form results in increased activity of CASP3 protein]	23639522
C008577	myricitrin	myricitrin inhibits the reaction [APOE gene mutant form results in increased expression of CCL2 protein]	23639522
C008577	myricitrin	myricitrin inhibits the reaction [APOE gene mutant form results in increased expression of CRP protein]	23639522
C008577	myricitrin	myricitrin inhibits the reaction [APOE gene mutant form results in increased expression of ICAM1 protein]	23639522
C063509	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of APOE mRNA]	22056562
C063509	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of APOE protein]	22056562
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of APOE mRNA"	25448806
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of APOE mRNA"	25554681
C017096	n-butoxyethanol	n-butoxyethanol results in decreased expression of APOE mRNA	19812364
D009532	Nickel	APOE protein binds to Nickel	23896426
D009532	Nickel	Nickel results in decreased expression of APOE mRNA	24768652\|2558310
C028007	nickel monoxide	nickel monoxide results in decreased expression of APOE mRNA	19167457
C029938	nickel sulfate	nickel sulfate results in decreased expression of APOE mRNA	16780908
C029938	nickel sulfate	nickel sulfate results in increased expression of APOE mRNA	16780908
D009538	Nicotine	Nicotine results in increased expression of APOE mRNA	17997037
C012655	nimesulide	nimesulide inhibits the reaction [APOE results in decreased expression of CCNA2 protein]	14966570
C012655	nimesulide	nimesulide inhibits the reaction [APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha]	14966570
D009569	Nitric Oxide	APOE gene mutant form results in decreased chemical synthesis of Nitric Oxide	11397713
C014707	nitrosobenzylmethylamine	nitrosobenzylmethylamine results in decreased expression of APOE mRNA	17616710
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA]	24933211
C072936	notoginsenoside R1	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]	24933211
C464660	obeticholic acid	obeticholic acid results in decreased expression of APOE mRNA	27939613
C025589	ochratoxin A	ochratoxin A results in increased expression of APOE mRNA	23358140
D015525	Fatty Acids, Omega-3	"Fatty Acids, Omega-3 results in decreased expression of APOE mRNA"	23333450
C030110	oxaliplatin	[oxaliplatin co-treated with Topotecan] results in increased expression of APOE mRNA	25729387
C030110	oxaliplatin	oxaliplatin results in increased expression of APOE mRNA	25729387
D010126	Ozone	Ozone results in decreased expression of APOE mRNA	12763052
D000073878	Palm Oil	Palm Oil results in decreased expression of APOE mRNA	18042831
C084656	paricalcitol	[Phosphorus co-treated with paricalcitol] results in decreased expression of APOE mRNA	17715259
C084656	paricalcitol	paricalcitol inhibits the reaction [APOE gene mutant form results in decreased abundance of Antioxidants]	25037058
C084656	paricalcitol	paricalcitol inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]	25037058
D052638	Particulate Matter	APOE gene mutant form affects the susceptibility to Particulate Matter	21222557\|2274640
D052638	Particulate Matter	[APOE gene mutant form affects the susceptibility to Particulate Matter] which results in increased expression of PTGIS mRNA	22746401
D052638	Particulate Matter	[APOE gene mutant form affects the susceptibility to Particulate Matter] which results in increased expression of PTGS2 mRNA	22746401
D052638	Particulate Matter	[APOE gene mutant form affects the susceptibility to Particulate Matter] which results in increased expression of PTGS2 protein	22746401
D052638	Particulate Matter	APOE protein affects the susceptibility to [Dietary Fats co-treated with Particulate Matter]	17655762
D052638	Particulate Matter	[APOE protein affects the susceptibility to [Dietary Fats co-treated with Particulate Matter]] which affects the expression of ATF4 mRNA	17655762
D052638	Particulate Matter	[APOE protein affects the susceptibility to [Dietary Fats co-treated with Particulate Matter]] which affects the expression of HMOX1 mRNA	17655762
D052638	Particulate Matter	[APOE protein affects the susceptibility to [Dietary Fats co-treated with Particulate Matter]] which affects the expression of XBP1 mRNA	17655762
D052638	Particulate Matter	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Particulate Matter results in increased expression of HMOX1 mRNA]	24330719
D052638	Particulate Matter	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]	24330719
D052638	Particulate Matter	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Particulate Matter results in increased expression of NQO1 mRNA]	24330719
D052638	Particulate Matter	APOE protein affects the susceptibility to Particulate Matter	17602821
D052638	Particulate Matter	[APOE protein affects the susceptibility to Particulate Matter] which results in increased expression of NOS2 mRNA	17602821
D010406	Penicillins	Cysteine Proteinase Inhibitors inhibits the reaction [Penicillins results in increased expression of APOE mRNA]	23266720
D010406	Penicillins	Cysteine Proteinase Inhibitors inhibits the reaction [Penicillins results in increased expression of APOE protein]	23266720
D010406	Penicillins	Penicillins results in increased expression of APOE mRNA	23266720
D010406	Penicillins	Penicillins results in increased expression of APOE protein	23266720
C086401	pentabromodiphenyl ether	pentabromodiphenyl ether analog results in increased expression of APOE mRNA	19095052
C046012	pentanal	pentanal results in increased expression of APOE mRNA	26079696
C036567	perfluorodecanoic acid	perfluorodecanoic acid results in decreased expression of APOE mRNA	21984479
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in increased expression of APOE protein	26178269
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in increased expression of APOE protein	22609092
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of APOE mRNA	21984479
D026023	Permethrin	[Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of APOE mRNA	28659758
D010634	Phenobarbital	Phenobarbital affects the expression of APOE protein	16099942
D010634	Phenobarbital	[Phenobarbital co-treated with Diethylnitrosamine] results in increased expression of APOE protein	20935162
D010656	Phenylephrine	APOE protein affects the susceptibility to Phenylephrine	17899169
D010672	Phenytoin	Phenytoin results in increased expression of APOE mRNA	15136057
D010758	Phosphorus	[Phosphorus co-treated with paricalcitol] results in decreased expression of APOE mRNA	17715259
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of CYP51 mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of CYP7B1 mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of FADS1 mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of FADS2 mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HMGCR mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HMGCS1 mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HSD17B7 mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of LPIN1 mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of PPARGC1B mRNA]	18155511
D010840	Phytosterols	APOE gene mutant form affects the reaction [Phytosterols results in increased expression of SQLE mRNA]	18155511
C006253	pirinixic acid	pirinixic acid affects the expression of APOE protein	16099942
D010936	Plant Extracts	Plant Extracts results in increased expression of APOE mRNA	21920417
D011078	Polychlorinated Biphenyls	Polychlorinated Biphenyls affects the expression of APOE mRNA	21334430
D011078	Polychlorinated Biphenyls	Polychlorinated Biphenyls results in increased expression of APOE mRNA	18077114
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine results in increased expression of APOE mRNA	24583197
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine results in increased expression of APOE mRNA	27989595
D059808	Polyphenols	Polyphenols results in decreased expression of APOE protein	16046716
D011137	Polystyrenes	Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein]	8461338
D011189	Potassium Chloride	"[Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary co-treated with Potassium Chloride] results in increased expression of APOE mRNA"	22228705
D011341	Probucol	APOE protein affects the susceptibility to Probucol	19394937
D011341	Probucol	APOE protein results in decreased susceptibility to Probucol	10998462
D011341	Probucol	Probucol promotes the reaction [APOE gene mutant form results in increased expression of C1QC mRNA]	19394937
D011341	Probucol	Probucol promotes the reaction [APOE gene mutant form results in increased expression of CXCR4 mRNA]	19394937
D011341	Probucol	Probucol promotes the reaction [APOE gene mutant form results in increased expression of DOCK2 mRNA]	19394937
D011341	Probucol	Probucol promotes the reaction [APOE gene mutant form results in increased expression of FCER1G mRNA]	19394937
D011341	Probucol	Probucol promotes the reaction [APOE gene mutant form results in increased expression of ITGB2 mRNA]	19394937
D011341	Probucol	Probucol promotes the reaction [APOE gene mutant form results in increased expression of LILRB3 mRNA]	19394937
D011341	Probucol	Probucol promotes the reaction [APOE gene mutant form results in increased expression of LY86 mRNA]	19394937
D011341	Probucol	Probucol promotes the reaction [APOE gene mutant form results in increased expression of SELPLG mRNA]	19394937
C005556	propionaldehyde	propionaldehyde results in increased expression of APOE mRNA	26079696
D011692	Puromycin Aminonucleoside	APOE protein results in decreased susceptibility to Puromycin Aminonucleoside	12472773
D011692	Puromycin Aminonucleoside	Puromycin Aminonucleoside affects the expression of APOE mRNA	8413767
D011692	Puromycin Aminonucleoside	Puromycin Aminonucleoside results in increased expression of APOE protein	7442475
C513428	pyrachlostrobin	pyrachlostrobin results in increased expression of APOE mRNA	27029645
D011729	Pyridostigmine Bromide	[Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of APOE mRNA	28659758
D011794	Quercetin	Quercetin results in increased expression of APOE mRNA	21632981
D011794	Quercetin	Quercetin inhibits the reaction [APOE gene mutant form results in decreased activity of NOS3 protein]	20093625
D011794	Quercetin	Quercetin inhibits the reaction [APOE gene mutant form results in increased expression of EDN1 protein]	20093625
D011794	Quercetin	Quercetin inhibits the reaction [APOE gene mutant form results in increased expression of PTGR1 protein]	20093625
D011794	Quercetin	Quercetin inhibits the reaction [APOE gene mutant form results in increased expression of SELP protein]	20093625
D011794	Quercetin	Quercetin inhibits the reaction [APOE gene mutant form results in increased susceptibility to Dietary Fats]	24017971
D011794	Quercetin	Quercetin promotes the reaction [APOE gene mutant form results in increased expression of HMOX1 protein]	20093625
D011794	Quercetin	Quercetin results in increased expression of APOE mRNA	16455785
C059514	resveratrol	resveratrol affects the secretion of APOE protein	24802182
C059514	resveratrol	resveratrol results in increased expression of APOE mRNA	19371625
C059514	resveratrol	resveratrol results in increased expression of APOE mRNA	22610192
C059514	resveratrol	resveratrol results in decreased expression of APOE mRNA	19228061
C059514	resveratrol	resveratrol results in decreased expression of APOE mRNA	23419489
D015474	Isotretinoin	APOE gene polymorphism affects the susceptibility to Isotretinoin	12622636
C009166	retinol acetate	retinol acetate results in increased expression of APOE mRNA	16772331
C089730	rosiglitazone	APOE gene polymorphism affects the susceptibility to rosiglitazone	16446752
C089730	rosiglitazone	rosiglitazone results in increased expression of APOE mRNA	16386711
C089730	rosiglitazone	rosiglitazone results in increased expression of APOE protein	16386711
D012402	Rotenone	APOE protein affects the susceptibility to Rotenone	28728140
C049705	S-1,2-dichlorovinyl-N-acetylcysteine	"S-1,2-dichlorovinyl-N-acetylcysteine affects the expression of APOE mRNA"	16844155
D012524	Sarin	Sarin results in increased expression of APOE mRNA	19522546
D012524	Sarin	Sarin results in increased expression of APOE protein	19522546
D012643	Selenium	Selenium results in increased expression of APOE mRNA	19244175
D012643	Selenium	Selenium affects the expression of APOE protein	17996733
D019821	Simvastatin	APOE polymorphism affects the susceptibility to Simvastatin	11849659\|1290152
D019821	Simvastatin	Simvastatin results in decreased expression of APOE	19461118
D019821	Simvastatin	Simvastatin results in decreased expression of APOE mRNA	18270459
D019821	Simvastatin	APOE affects the susceptibility to Simvastatin	11947894
D019821	Simvastatin	Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein]	8461338
D019821	Simvastatin	Simvastatin results in decreased expression of APOE mRNA	25055962\|8289597
D019821	Simvastatin	Simvastatin results in decreased expression of APOE protein	8461338
C017947	sodium arsenite	sodium arsenite affects the methylation of APOE gene	28589171
C017947	sodium arsenite	sodium arsenite results in increased expression of APOE mRNA	28229933
C017947	sodium arsenite	APOE gene mutant form affects the susceptibility to sodium arsenite	19682479
C017947	sodium arsenite	[APOE gene mutant form affects the susceptibility to sodium arsenite] which results in increased expression of CCL2 protein	19682479
C017947	sodium arsenite	[APOE gene mutant form affects the susceptibility to sodium arsenite] which results in increased expression of IL6 mRNA	19682479
C017947	sodium arsenite	[APOE gene mutant form affects the susceptibility to sodium arsenite] which results in increased expression of IL6 protein	19682479
C017947	sodium arsenite	APOE gene mutant form results in increased susceptibility to sodium arsenite	14594625
C017947	sodium arsenite	APOE protein affects the susceptibility to sodium arsenite	28728140
C017947	sodium arsenite	[APOE protein affects the susceptibility to sodium arsenite] which results in decreased expression of ACTA2 protein	28728140
C017947	sodium arsenite	AS3MT protein affects the reaction [APOE protein affects the susceptibility to sodium arsenite]	28728140
C017947	sodium arsenite	AS3MT protein affects the reaction [[APOE protein affects the susceptibility to sodium arsenite] which results in decreased expression of ACTA2 protein]	28728140
C017947	sodium arsenite	cocoa butter promotes the reaction [APOE gene mutant form results in increased susceptibility to sodium arsenite]	14594625
C017947	sodium arsenite	sodium arsenite results in decreased expression of APOE mRNA	19822182
C016104	sodium bichromate	sodium bichromate results in increased expression of APOE mRNA	22561333
D017673	Sodium Chloride, Dietary	"[Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary co-treated with Potassium Chloride] results in increased expression of APOE mRNA"	22228705
D012969	Sodium Fluoride	Sodium Fluoride results in increased expression of APOE protein	28918527
D013311	Streptozocin	INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]	16380481
D013311	Streptozocin	[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine	16380481
D013311	Streptozocin	Streptozocin results in increased expression of APOE mRNA	16684804
D013311	Streptozocin	vanadyl sulfate inhibits the reaction [Streptozocin results in increased expression of APOE mRNA]	16684804
D013481	Superoxides	APOE gene mutant form results in increased abundance of Superoxides	11397713
D013481	Superoxides	APOE gene mutant form results in increased chemical synthesis of Superoxides	12871831
D013481	Superoxides	imisopasem manganese inhibits the reaction [APOE gene mutant form results in increased chemical synthesis of Superoxides]	12871831
D013481	Superoxides	manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [APOE gene mutant form results in increased abundance of Superoxides]	11397713
D014284	Triiodothyronine	Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein]	6816881
D013605	T-2 Toxin	T-2 Toxin results in increased expression of APOE mRNA	26141394
D013629	Tamoxifen	APOE gene polymorphism affects the susceptibility to Tamoxifen	19103187
D013629	Tamoxifen	Tamoxifen affects the expression of APOE mRNA	17555576
D013656	Taurocholic Acid	[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein	6631239
C001803	tempol	tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]	20530721
C001803	tempol	tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]	20530721
C004648	testosterone enanthate	[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of APOE mRNA	18160741
C004648	testosterone enanthate	[cetrorelix co-treated with testosterone enanthate] results in decreased expression of APOE mRNA	18160741
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of APOE mRNA	20106945\|2163298
D013749	Tetrachlorodibenzodioxin	APOE protein affects the susceptibility to Tetrachlorodibenzodioxin	12213967\|2144114
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of APOE mRNA	21570461\|2468072
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of APOE mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of APOE mRNA	21041162
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of APOE mRNA	15703262
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of APOE mRNA	16267337
C056068	theaflavin	theaflavin inhibits the reaction [APOE gene mutant form results in decreased activity of NOS3 protein]	20093625
C056068	theaflavin	theaflavin inhibits the reaction [APOE gene mutant form results in increased expression of PTGR1 protein]	20093625
C056068	theaflavin	theaflavin inhibits the reaction [APOE gene mutant form results in increased expression of SELP protein]	20093625
C009495	titanium dioxide	titanium dioxide results in decreased expression of APOE mRNA	23557971
C009495	titanium dioxide	titanium dioxide results in increased expression of APOE mRNA	23131501
C423915	TO-901317	TO-901317 results in increased expression of APOE mRNA	17449538
C423915	TO-901317	TO-901317 results in increased expression of APOE mRNA	19665519
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of APOE mRNA	28065790
D014028	Tobacco Smoke Pollution	APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in decreased expression of CYP2F2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in decreased expression of CYP2S1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in decreased expression of GSTA2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in decreased expression of KITL mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in decreased expression of PLAT mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in decreased expression of VEGFA mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of ADH7 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of ALDH3B2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of APCS protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of BID mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of C1QB mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of C1QC mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of C3AR1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CBR3 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL11 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL12 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL12 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL19 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL19 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL2 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL4 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL7 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL7 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL9 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL9 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CD276 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CD86 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CD86 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CRLF1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CRP protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CSF1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CSF1 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CSF2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CSF2 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL10 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL10 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL12 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL2 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL5 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL5 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CYP1B1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CYP2B10 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CYP4F39 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of F13A1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of F3 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGF2 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGF9 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGG protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of GSTM1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of GSTO1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of GSTP1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of H2-AB1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of HIST1H1C mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of HSD11B1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IFNG protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IGF1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IGFBP2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL11 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL18 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL18 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL1A mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL1A protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL6 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL6 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL7 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of ITGAM protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of KITL protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of LCN2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of MFGE8 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of MLEC mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of MMP9 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of NUDT19 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of OCIAD2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of PA2G4 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of PER3 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of PF4 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of PIGR mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of SERPINA3N mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of SRXN1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of SULF2 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of TIMP1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of TIMP1 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of TNF protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of VCAM1 mRNA	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of VCAM1 protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of VEGFA protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of VWF protein	24096154
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of WNT5A mRNA	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in decreased expression of PLAT mRNA]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of APCS protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL12 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL19 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL2 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL4 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL7 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CCL9 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CD86 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CRP protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CSF1 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CSF2 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL10 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL2 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of CXCL5 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of F3 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGF2 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGF9 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of ICAM1 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IFNG protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL11 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL18 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL1A protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL6 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of IL7 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of ITGAM protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of KITL protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of MMP9 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of TIMP1 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of TNF protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of VCAM1 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of VEGFA protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of VWF protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]	22659316
C024746	tobacco tar	tobacco tar results in decreased expression of APOE mRNA	19559774
C066340	tolcapone	tolcapone binds to APOE protein	19783845
D019772	Topotecan	[oxaliplatin co-treated with Topotecan] results in increased expression of APOE mRNA	25729387
D019772	Topotecan	Topotecan results in increased expression of APOE mRNA	25729387
D014108	Tosylphenylalanyl Chloromethyl Ketone	Tosylphenylalanyl Chloromethyl Ketone promotes the reaction [APOA1 protein results in increased expression of APOE mRNA]	22056562
D014108	Tosylphenylalanyl Chloromethyl Ketone	Tosylphenylalanyl Chloromethyl Ketone promotes the reaction [APOA1 protein results in increased secretion of APOE protein]	22056562
D014118	Toxins, Biological	"Toxins, Biological affects the expression of APOE mRNA"	19682533
D014212	Tretinoin	Tretinoin results in decreased expression of APOE mRNA	23724009
D014212	Tretinoin	AGN 193109 inhibits the reaction [Tretinoin results in increased expression of APOE mRNA]	16505366
D014212	Tretinoin	Tretinoin results in increased expression of APOE mRNA	16505366
D014280	Triglycerides	[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Triglycerides	21908651
D014280	Triglycerides	APOE gene mutant form results in increased abundance of Triglycerides	24933211
D014280	Triglycerides	Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Triglycerides]	21908651
D014280	Triglycerides	notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]	24933211
D014282	Trihexyphenidyl	APOE gene polymorphism results in increased susceptibility to Trihexyphenidyl	18239197
C015559	trimellitic anhydride	trimellitic anhydride results in decreased expression of APOE mRNA	19042947
D014304	Triolein	[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein	6631239
C016805	tris(1,3-dichloro-2-propyl)phosphate	"APOE protein affects the susceptibility to tris(1,3-dichloro-2-propyl)phosphate"	24407104
C057693	troglitazone	troglitazone results in increased expression of APOE mRNA	19140230
D014331	Tropicamide	APOE gene polymorphism results in increased susceptibility to Tropicamide	8724673\|9137131
C002802	tungsten carbide	[tungsten carbide co-treated with Cobalt] results in decreased expression of APOE mRNA	18078969
D014635	Valproic Acid	Valproic Acid affects the expression of APOE mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of APOE mRNA	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of APOE mRNA	23179753
D014635	Valproic Acid	Valproic Acid promotes the reaction [Mechlorethamine results in increased expression of APOE mRNA]	28184907
D000068756	Valsartan	[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin Calcium co-treated with Valsartan] results in decreased expression of APOE protein	19603250
D000068756	Valsartan	Valsartan inhibits the reaction [AGT protein results in decreased expression of APOE protein]	17785354
C034028	vanadyl sulfate	vanadyl sulfate inhibits the reaction [Streptozocin results in increased expression of APOE mRNA]	16684804
D000068580	Varenicline	APOE protein affects the susceptibility to Varenicline	28202387
D001335	Vehicle Emissions	APOE gene mutant form affects the susceptibility to Vehicle Emissions	21222557\|2274640
D001335	Vehicle Emissions	[APOE gene mutant form affects the susceptibility to Vehicle Emissions] which results in increased expression of PTGIS mRNA	22746401
D001335	Vehicle Emissions	[APOE gene mutant form affects the susceptibility to Vehicle Emissions] which results in increased expression of PTGS2 mRNA	22746401
D001335	Vehicle Emissions	[APOE gene mutant form affects the susceptibility to Vehicle Emissions] which results in increased expression of PTGS2 protein	22746401
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Vehicle Emissions results in increased expression of HMOX1 mRNA]	24330719
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Vehicle Emissions results in increased expression of NFE2L2 mRNA]	24330719
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Dietary Fats] promotes the reaction [Vehicle Emissions results in increased expression of NQO1 mRNA]	24330719
D001335	Vehicle Emissions	APOE protein affects the susceptibility to Vehicle Emissions	17602821\|1915088
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of EDN1 mRNA	19150882
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of MMP2 mRNA	19150882
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of MMP2 protein	19150882
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of MMP9 mRNA	19150882
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of MMP9 protein	19150882
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of NOS2 mRNA	17602821
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of TIMP2 mRNA	19150882
D001335	Vehicle Emissions	[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of TIMP2 protein	19150882
D001335	Vehicle Emissions	cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of EDN1 mRNA]	19150882
D001335	Vehicle Emissions	cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of MMP9 mRNA]	19150882
D001335	Vehicle Emissions	cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [[APOE protein affects the susceptibility to Vehicle Emissions] which results in increased expression of MMP9 protein]	19150882
D001335	Vehicle Emissions	Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]	19891982
D001335	Vehicle Emissions	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in decreased expression of MMP13 mRNA	19891982
D001335	Vehicle Emissions	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in decreased expression of MMP8 mRNA	19891982
D001335	Vehicle Emissions	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in increased expression of EDN1 mRNA	19891982
D001335	Vehicle Emissions	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in increased expression of MMP9 mRNA	19891982
D001335	Vehicle Emissions	[Vehicle Emissions affects the reaction [APOE gene mutant form affects the susceptibility to Dietary Fats]] which results in increased expression of TIMP2 mRNA	19891982
C029297	vinylidene chloride	vinylidene chloride results in increased expression of APOE mRNA	26682919
D014810	Vitamin E	"Vitamin E inhibits the reaction [APOE mutant form results in increased abundance of 8,12-iso-isoprostane F2alpha-VI]"	16303615
D014812	Vitamin K	APOE protein affects the abundance of Vitamin K	15952022
D014812	Vitamin K	APOE protein affects the uptake of Vitamin K	16847429
D024483	Vitamin K 3	APOE protein affects the susceptibility to Vitamin K 3	28728140
D014859	Warfarin	APOE gene mutant form affects the susceptibility to Warfarin	21228733
D014859	Warfarin	APOE gene polymorphism affects the susceptibility to Warfarin	16847429\|1704800
D014859	Warfarin	APOE polymorphism affects the susceptibility to Warfarin	25312789
D014859	Warfarin	APOE protein affects the susceptibility to Warfarin	15952022
D014859	Warfarin	APOE SNP affects the susceptibility to Warfarin	28079798
D014859	Warfarin	APOE gene mutant form results in increased susceptibility to Warfarin	23415960
D015032	Zinc	APOE protein binds to Zinc	23896426
D019287	Zinc Sulfate	Zinc Sulfate results in increased expression of APOE mRNA	1883846
D019287	Zinc Sulfate	Zinc Sulfate results in increased expression of APOE protein	1883846

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001540	amyloid-beta binding	-	IBA	21873635
GO:0001540	amyloid-beta binding	-	IDA	8089103 11305869 25207746
GO:0001540	amyloid-beta binding	-	IPI	9003062 9211985 22138302
GO:0005198	structural molecule activity	-	TAS	22138302
GO:0005319	lipid transporter activity	-	IDA	17305370
GO:0005515	protein binding	-	IPI	7972031 8245722 12950167 19758344 21163940 21593558 24447298 25122793
GO:0005543	phospholipid binding	-	IBA	21873635
GO:0005543	phospholipid binding	-	IDA	4066713
GO:0008201	heparin binding	-	IDA	2745454
GO:0008289	lipid binding	-	IDA	4066713
GO:0015485	cholesterol binding	-	IBA	21873635
GO:0016209	antioxidant activity	-	IDA	9685360
GO:0017127	cholesterol transporter activity	-	IBA	21873635
GO:0042802	identical protein binding	-	IDA	4066713
GO:0042803	protein homodimerization activity	-	IDA	8089103 9211985
GO:0042803	protein homodimerization activity	-	IPI	8245722
GO:0044877	protein-containing complex binding	-	IDA	25207746
GO:0046911	metal chelating activity	-	IDA	9685360
GO:0046983	protein dimerization activity	-	IDA	22138302
GO:0048156	tau protein binding	-	IPI	7566652
GO:0050750	low-density lipoprotein particle receptor binding	-	IBA	21873635
GO:0050750	low-density lipoprotein particle receptor binding	-	IDA	210175
GO:0050750	low-density lipoprotein particle receptor binding	-	IPI	17326667
GO:0050750	low-density lipoprotein particle receptor binding	-	NAS	20005821
GO:0060228	phosphatidylcholine-sterol O-acyltransferase activator activity	-	IBA	21873635
GO:0060228	phosphatidylcholine-sterol O-acyltransferase activator activity	-	IDA	15654758
GO:0070326	very-low-density lipoprotein particle receptor binding	-	IBA	21873635
GO:0070326	very-low-density lipoprotein particle receptor binding	-	IDA	1384047
GO:0070326	very-low-density lipoprotein particle receptor binding	-	IPI	12950167
GO:0071813	lipoprotein particle binding	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000302	response to reactive oxygen species	-	NAS	11743999
GO:0001523	retinoid metabolic process	-	TAS	-
GO:0001937	negative regulation of endothelial cell proliferation	-	IDA	9685360
GO:0002021	response to dietary excess	-	IEA	-
GO:0006357	regulation of transcription by RNA polymerase II	-	TAS	-
GO:0006641	triglyceride metabolic process	-	IDA	9649566
GO:0006641	triglyceride metabolic process	-	IMP	3771793
GO:0006695	cholesterol biosynthetic process	-	IBA	21873635
GO:0006707	cholesterol catabolic process	-	IBA	21873635
GO:0006874	cellular calcium ion homeostasis	-	IEA	-
GO:0006898	receptor-mediated endocytosis	-	IDA	1917954
GO:0006898	receptor-mediated endocytosis	-	TAS	22138302
GO:0007010	cytoskeleton organization	-	TAS	9622609
GO:0007186	G-protein coupled receptor signaling pathway	-	IDA	16443932
GO:0007263	nitric oxide mediated signal transduction	-	IDA	8995232
GO:0007271	synaptic transmission, cholinergic	-	TAS	9622609
GO:0007616	long-term memory	-	IGI	24412220
GO:0008203	cholesterol metabolic process	-	IDA	9649566
GO:0008203	cholesterol metabolic process	-	IMP	3771793
GO:0010544	negative regulation of platelet activation	-	IDA	8995232
GO:0010629	negative regulation of gene expression	-	ISS	-
GO:0010873	positive regulation of cholesterol esterification	-	IBA	21873635
GO:0010873	positive regulation of cholesterol esterification	-	IDA	15654758
GO:0010875	positive regulation of cholesterol efflux	-	IDA	12042316 14754908
GO:0010875	positive regulation of cholesterol efflux	-	IGI	12401887
GO:0010877	lipid transport involved in lipid storage	-	ISS	-
GO:0010976	positive regulation of neuron projection development	-	IDA	7592957 23845000
GO:0010976	positive regulation of neuron projection development	-	ISS	-
GO:0010977	negative regulation of neuron projection development	-	IDA	7592957
GO:0015909	long-chain fatty acid transport	-	IDA	24345162
GO:0017038	protein import	-	IDA	24446231
GO:0019068	virion assembly	-	IMP	25122793
GO:0019433	triglyceride catabolic process	-	IBA	21873635
GO:0019934	cGMP-mediated signaling	-	IDA	8995232
GO:0030195	negative regulation of blood coagulation	-	IDA	8995232
GO:0030516	regulation of axon extension	-	TAS	9622609
GO:0031102	neuron projection regeneration	-	IBA	21873635
GO:0032269	negative regulation of cellular protein metabolic process	-	IGI	16805831
GO:0032374	regulation of cholesterol transport	-	IBA	21873635
GO:0032462	regulation of protein homooligomerization	-	IDA	25207746
GO:0032489	regulation of Cdc42 protein signal transduction	-	IDA	16443932
GO:0032805	positive regulation of low-density lipoprotein particle receptor catabolic process	-	IDA	15950758
GO:0033344	cholesterol efflux	-	IBA	21873635
GO:0033344	cholesterol efflux	-	IDA	11162594 16443932
GO:0033700	phospholipid efflux	-	IBA	21873635
GO:0033700	phospholipid efflux	-	IDA	11162594
GO:0034371	chylomicron remodeling	-	TAS	-
GO:0034372	very-low-density lipoprotein particle remodeling	-	IBA	21873635
GO:0034372	very-low-density lipoprotein particle remodeling	-	IDA	15654758
GO:0034372	very-low-density lipoprotein particle remodeling	-	IGI	12401887
GO:0034374	low-density lipoprotein particle remodeling	-	IEA	-
GO:0034375	high-density lipoprotein particle remodeling	-	IGI	12401887
GO:0034375	high-density lipoprotein particle remodeling	-	TAS	-
GO:0034378	chylomicron assembly	-	TAS	-
GO:0034380	high-density lipoprotein particle assembly	-	IBA	21873635
GO:0034380	high-density lipoprotein particle assembly	-	IDA	17305370
GO:0034382	chylomicron remnant clearance	-	IMP	7175379
GO:0034382	chylomicron remnant clearance	-	TAS	-
GO:0034384	high-density lipoprotein particle clearance	-	IDA	210175
GO:0034447	very-low-density lipoprotein particle clearance	-	IDA	1917954
GO:0034447	very-low-density lipoprotein particle clearance	-	IMP	9649566
GO:0035641	locomotory exploration behavior	-	IMP	24412220
GO:0042157	lipoprotein metabolic process	-	IBA	21873635
GO:0042158	lipoprotein biosynthetic process	-	IEA	-
GO:0042159	lipoprotein catabolic process	-	IBA	21873635
GO:0042311	vasodilation	-	IEA	-
GO:0042632	cholesterol homeostasis	-	IBA	21873635
GO:0042632	cholesterol homeostasis	-	IDA	9649566
GO:0042632	cholesterol homeostasis	-	IGI	24412220
GO:0042982	amyloid precursor protein metabolic process	-	IDA	21593558
GO:0043407	negative regulation of MAP kinase activity	-	IDA	9685360
GO:0043524	negative regulation of neuron apoptotic process	-	IBA	21873635
GO:0043537	negative regulation of blood vessel endothelial cell migration	-	IDA	9685360
GO:0043687	post-translational protein modification	-	TAS	-
GO:0043691	reverse cholesterol transport	-	IBA	21873635
GO:0043691	reverse cholesterol transport	-	IDA	8127890
GO:0044267	cellular protein metabolic process	-	TAS	-
GO:0044794	positive regulation by host of viral process	-	IMP	25122793
GO:0045541	negative regulation of cholesterol biosynthetic process	-	IDA	1917954
GO:0045807	positive regulation of endocytosis	-	IDA	7683668 8300609
GO:0046889	positive regulation of lipid biosynthetic process	-	IBA	21873635
GO:0046889	positive regulation of lipid biosynthetic process	-	IDA	12042316
GO:0046907	intracellular transport	-	TAS	9622609
GO:0048168	regulation of neuronal synaptic plasticity	-	TAS	9622609
GO:0048844	artery morphogenesis	-	IEA	-
GO:0050728	negative regulation of inflammatory response	-	IC	8995232
GO:0051000	positive regulation of nitric-oxide synthase activity	-	IBA	21873635
GO:0051000	positive regulation of nitric-oxide synthase activity	-	IDA	8995232
GO:0051044	positive regulation of membrane protein ectodomain proteolysis	-	IDA	15950758
GO:0051044	positive regulation of membrane protein ectodomain proteolysis	-	IGI	25015123
GO:0051246	regulation of protein metabolic process	-	IGI	24412220
GO:0051651	maintenance of location in cell	-	IEA	-
GO:0055089	fatty acid homeostasis	-	IDA	24345162
GO:0060999	positive regulation of dendritic spine development	-	IDA	24328732
GO:0061771	response to caloric restriction	-	IGI	24412220
GO:0070328	triglyceride homeostasis	-	ISS	-
GO:0090090	negative regulation of canonical Wnt signaling pathway	-	IDA	16805831
GO:0090090	negative regulation of canonical Wnt signaling pathway	-	IGI	16805831
GO:0090090	negative regulation of canonical Wnt signaling pathway	-	TAS	22988876
GO:0090181	regulation of cholesterol metabolic process	-	IGI	24412220
GO:0090209	negative regulation of triglyceride metabolic process	-	IEA	-
GO:0097113	AMPA glutamate receptor clustering	-	IDA	24328732
GO:0097114	NMDA glutamate receptor clustering	-	IDA	24328732
GO:0098869	cellular oxidant detoxification	-	IEA	-
GO:1900221	regulation of amyloid-beta clearance	-	IBA	21873635
GO:1900221	regulation of amyloid-beta clearance	-	IDA	24446231
GO:1900272	negative regulation of long-term synaptic potentiation	-	IDA	16273551
GO:1901215	negative regulation of neuron death	-	IDA	24259049
GO:1901628	positive regulation of postsynaptic membrane organization	-	IDA	24259049
GO:1901630	negative regulation of presynaptic membrane organization	-	IDA	24259049
GO:1902430	negative regulation of amyloid-beta formation	-	IDA	24154541
GO:1902952	positive regulation of dendritic spine maintenance	-	IDA	24328732
GO:1902995	positive regulation of phospholipid efflux	-	IDA	12042316
GO:1903002	positive regulation of lipid transport across blood brain barrier	-	IDA	24345162
GO:1905855	positive regulation of heparan sulfate binding	-	IDA	7683668
GO:1905860	positive regulation of heparan sulfate proteoglycan binding	-	IDA	8300609
GO:1905890	regulation of cellular response to very-low-density lipoprotein particle stimulus	-	IDA	7592957
GO:1905906	regulation of amyloid fibril formation	-	IDA	25207746
GO:1905908	positive regulation of amyloid fibril formation	-	TAS	9228033 20005821
GO:2000822	regulation of behavioral fear response	-	IMP	24412220

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005576	extracellular region	-	HDA	27068509
GO:0005576	extracellular region	-	IDA	8089103 16805831
GO:0005576	extracellular region	-	TAS	-
GO:0005615	extracellular space	-	HDA	16502470 20551380
GO:0005615	extracellular space	-	ISS	-
GO:0005634	nucleus	-	HDA	21630459
GO:0005737	cytoplasm	-	NAS	8083695
GO:0005737	cytoplasm	-	TAS	9622609
GO:0005769	early endosome	-	TAS	-
GO:0005783	endoplasmic reticulum	-	IDA	25122793
GO:0005788	endoplasmic reticulum lumen	-	TAS	-
GO:0005794	Golgi apparatus	-	IDA	25122793
GO:0005886	plasma membrane	-	TAS	-
GO:0016020	membrane	-	HDA	19946888
GO:0030425	dendrite	-	NAS	8083695
GO:0030669	clathrin-coated endocytic vesicle membrane	-	TAS	-
GO:0031012	extracellular matrix	-	HDA	23658023
GO:0034361	very-low-density lipoprotein particle	-	IDA	8245722 9211985 17154273 22138302
GO:0034362	low-density lipoprotein particle	-	IDA	8245722 9211985 22138302
GO:0034363	intermediate-density lipoprotein particle	-	IBA	21873635
GO:0034363	intermediate-density lipoprotein particle	-	IDA	9211985 17336988 22138302
GO:0034364	high-density lipoprotein particle	-	IBA	21873635
GO:0034364	high-density lipoprotein particle	-	IDA	210174 9211985 22138302
GO:0034365	discoidal high-density lipoprotein particle	-	TAS	22383525
GO:0042627	chylomicron	-	IBA	21873635
GO:0042627	chylomicron	-	IDA	8245722 16935699
GO:0043025	neuronal cell body	-	NAS	8083695
GO:0062023	collagen-containing extracellular matrix	-	HDA	27559042
GO:0070062	extracellular exosome	-	HDA	19056867 20458337 23533145
GO:0071682	endocytic vesicle lumen	-	TAS	-
GO:0072562	blood microparticle	-	HDA	22516433
GO:1903561	extracellular vesicle	-	HDA	24769233
GO:1990777	lipoprotein particle	-	IDA	22138302

KEGG ID	KEGG Term
hsa05010	Alzheimer's disease

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	IEA
R-HSA-1430728	Metabolism	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-174824	Plasma lipoprotein assembly, remodeling, and clearance	TAS
R-HSA-174824	Plasma lipoprotein assembly, remodeling, and clearance	IEA
R-HSA-196854	Metabolism of vitamins and cofactors	IEA
R-HSA-196854	Metabolism of vitamins and cofactors	TAS
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-2173782	Binding and Uptake of Ligands by Scavenger Receptors	IEA
R-HSA-2173782	Binding and Uptake of Ligands by Scavenger Receptors	TAS
R-HSA-2187338	Visual phototransduction	IEA
R-HSA-2187338	Visual phototransduction	TAS
R-HSA-3000480	Scavenging by Class A Receptors	IEA
R-HSA-3000480	Scavenging by Class A Receptors	TAS
R-HSA-372790	Signaling by GPCR	IEA
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	TAS
R-HSA-382551	Transport of small molecules	TAS
R-HSA-382551	Transport of small molecules	IEA
R-HSA-388396	GPCR downstream signalling	IEA
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-418594	G alpha (i) signalling events	IEA
R-HSA-418594	G alpha (i) signalling events	TAS
R-HSA-5653656	Vesicle-mediated transport	IEA
R-HSA-5653656	Vesicle-mediated transport	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-6806667	Metabolism of fat-soluble vitamins	IEA
R-HSA-6806667	Metabolism of fat-soluble vitamins	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	TAS
R-HSA-8957275	Post-translational protein phosphorylation	TAS
R-HSA-8963888	Chylomicron assembly	TAS
R-HSA-8963898	Plasma lipoprotein assembly	TAS
R-HSA-8963899	Plasma lipoprotein remodeling	TAS
R-HSA-8963901	Chylomicron remodeling	TAS
R-HSA-8964026	Chylomicron clearance	TAS
R-HSA-8964026	Chylomicron clearance	IEA
R-HSA-8964043	Plasma lipoprotein clearance	TAS
R-HSA-8964043	Plasma lipoprotein clearance	IEA
R-HSA-8964058	HDL remodeling	TAS
R-HSA-975634	Retinoid metabolism and transport	IEA
R-HSA-975634	Retinoid metabolism and transport	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
19742390	From mild cognitive impairment to Alzheimer's disease - influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up. (2009 Jul-Aug)	Siuda J	Neurol Neurochir Pol
10861896	Apo E genotype, diabetes, and peripheral arterial disease in older men: the Honolulu Asia-aging study. (2000 Jul)	Resnick HE	Genet Epidemiol
11988615	Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. (2002 May)	Djousse L	Stroke
15010349	Genes related to vascular disease (APOE, VLDL-R, DCP-1) and other vascular factors in late-life depression. (2004 Mar-Apr)	Cervilla J	Am J Geriatr Psychiatry
17240409	Corpus callosum size, reaction time speed and variability in mild cognitive disorders and in a normative sample. (2007 Apr 9)	Anstey KJ	Neuropsychologia
7986307	The contribution of lipids to coronary heart disease in diabetes mellitus. (1994)	Stewart MW	J Intern Med Suppl
29066899	Sex differences in obesity and cognitive function in a cognitively normal aging Chinese Han population. (2017)	Li W	Neuropsychiatr Dis Treat
20032288	Cancer linked to Alzheimer disease but not vascular dementia. (2010 Jan 12)	Roe CM	Neurology
17502288	Interaction between genes and environment in neurodegenerative diseases. (2007 Apr)	Elbaz A	C R Biol
25803052	Association between tooth loss and cognitive function among 3063 Chinese older adults: a community-based study. (2015)	Luo J	PLoS One
23102783	Modulation of atherogenic lipidome by cigarette smoke in apolipoprotein E-deficient mice. (2012 Dec)	Boue S	Atherosclerosis
24391822	Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. (2013)	Guymer RH	PLoS One
28399252	Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. (2017 Apr 11)	Gottesman RF	JAMA
26912649	White matter hyperintensities and imaging patterns of brain ageing in the general population. (2016 Apr)	Habes M	Brain
20693183	Apolipoprotein E genotype and mortality in Southern European and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study. (2010 Oct)	Davis WA	Eur J Endocrinol
25471390	Rates and risk factors for progression to incident dementia vary by age in a population cohort. (2015 Jan 6)	Ganguli M	Neurology
20129626	Association of ALS with head injury, cigarette smoking and APOE genotypes. (2010 Apr 15)	Schmidt S	J Neurol Sci
17006673	Subsets of SNPs define rare genotype classes that predict ischemic heart disease. (2007 Feb)	Frikke-Schmidt R	Hum Genet
16239176	Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. (2005 Nov)	Rovio S	Lancet Neurol
11007687	Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. (2000 Oct)	Guz G	Am J Kidney Dis
25491588	Association between the catechol-O-methyltransferase polymorphism Val158Met and Alzheimer's disease in a Japanese population. (2015 Sep)	Shibata N	Int J Geriatr Psychiatry
20107178	Apolipoprotein E genotype is associated with macular pigment optical density. (2010 May)	Loane E	Invest Ophthalmol Vis Sci
28275046	Self-reported sleep disturbance and incidence of dementia in ageing men. (2017 Apr)	Luojus MK	J Epidemiol Community Health
28086795	Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study. (2017 Jan 13)	Fawzy MS	BMC Cardiovasc Disord
14726545	Synergistic effect of apolipoprotein E polymorphisms and cigarette smoking on risk of ischemic stroke in young adults. (2004 Feb)	Pezzini A	Stroke
29188888	Late-Life Body Mass Index, Rapid Weight Loss, Apolipoprotein E epsilon4 and the Risk of Cognitive Decline and Incident Dementia. (2017)	Bell SP	J Nutr Health Aging
21500874	Preventing Alzheimer's disease and cognitive decline. (2010 Apr)	Williams JW	Evid Rep Technol Assess (Full Rep)
20847559	Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer's disease: a population-based cardiovascular risk factors, aging and dementia study. (2010)	Rusanen M	Dement Geriatr Cogn Disord
24201835	Polymorphisms in the aldehyde dehydrogenase 2 and dopamine beta hydroxylase genes are not associated with Alzheimer's disease. (2014 Apr)	Komatsu M	J Neural Transm (Vienna)
10827377	Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. (2000 Jun)	Brscic E	Am Heart J
24955992	Structure and correlates of cognitive aging in a narrow age cohort. (2014 Jun)	Tucker-Drob EM	Psychol Aging
17210854	Apolipoprotein e gene and age-related maculopathy in older individuals: the cardiovascular health study. (2007 Jan)	Tikellis G	Arch Ophthalmol
18334912	Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. (2008 Apr)	Donnelly LA	Pharmacogenet Genomics
23246920	Metabolic syndrome and amnestic mild cognitive impairment: Singapore Longitudinal Ageing Study-2 findings. (2013)	Feng L	J Alzheimers Dis
17210851	Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. (2007 Jan)	DeAngelis MM	Arch Ophthalmol
10449113	APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. (1999 Aug 11)	Romas SN	Neurology
16449871	Apolipoprotein E polymorphism and preclinical carotid artery disease in untreated hypertensive men. (2006 Feb)	Bleil ME	Eur J Cardiovasc Prev Rehabil
17708369	Evaluation of apolipoprotein E (apoE) and lipoprotein profile in severe alcohol-dependent individuals. (2007 Jul-Aug)	Liappas IA	In Vivo
19181718	APOE-epsilon4, depressive symptoms, and cognitive decline in Chinese older adults: Singapore Longitudinal Aging Studies. (2009 Feb)	Niti M	J Gerontol A Biol Sci Med Sci
28550245	Amyloid Burden in Obstructive Sleep Apnea. (2017)	Yun CH	J Alzheimers Dis
11286640	Genetic determinants of plasma triglycerides: impact of rare and common mutations. (2001 May)	Talmud PJ	Curr Atheroscler Rep
27335042	Alzheimer's Disease and the Early Signs of Age-Related Macular Degeneration. (2016)	Frost S	Curr Alzheimer Res
26130946	APOE Polymorphism Is Associated with C-reactive Protein Levels but Not with White Blood Cell Count: Dong-gu Study and Namwon Study. (2015 Jul)	Yun YW	J Korean Med Sci
21649613	Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: the Hisayama Study. (2011 Jun)	Ohara T	J Am Geriatr Soc
18704761	Molecular genetics of myocardial infarction. (2008 Jan)	Yamada Y	Genomic Med
28031419	Serum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study. (2017 Mar)	Brahimaj A	Diabetes Care
17306734	Gene-environment interaction and its impact on coronary heart disease risk. (2007 Feb)	Talmud PJ	Nutr Metab Cardiovasc Dis
11368996	Sidestream cigarette smoke accelerates atherogenesis in apolipoprotein E-/- mice. (2001 May)	Gairola CG	Atherosclerosis
27396856	Hypoxanthine induces cholesterol accumulation and incites atherosclerosis in apolipoprotein E-deficient mice and cells. (2016 Nov)	Ryu HM	J Cell Mol Med
22961963	Lipoprotein phospholipase A2 and cerebral microbleeds in the Framingham Heart Study. (2012 Nov)	Romero JR	Stroke
26010393	Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease. (2015 Aug)	de Oliveira FF	Clin Neurol Neurosurg
20675872	[Risk factors for Alzheimer's disease]. (2010 Jul)	Ikeda T	Brain Nerve
21303575	Adherence to a Mediterranean diet and plasma fatty acids: data from the Bordeaux sample of the Three-City study. (2011 Jul)	Feart C	Br J Nutr
25080185	Prenatal stress enhances severity of atherosclerosis in the adult apolipoprotein E-deficient mouse offspring via inflammatory pathways. (2013 Feb)	Ho H	J Dev Orig Health Dis
12404343	A unifying hypothesis of Alzheimer's disease. III. Risk factors. (2000 Jan)	Heininger K	Hum Psychopharmacol
22407430	Consistency between cross-sectional and longitudinal SNP: blood lipid associations. (2012 Feb)	Costanza MC	Eur J Epidemiol
29036813	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. (2017)	Reijs BLR	J Alzheimers Dis
19595949	Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy. (2007 Oct)	Massoud F	Alzheimers Dement
19595865	Statin use and the risk of Alzheimer's disease: the MIRAGE study. (2006 Apr)	Green RC	Alzheimers Dement
29234777	Physical Activity and beta-Amyloid Brain Levels in Humans: A Systematic Review. (2015)	de Souto Barreto P	J Prev Alzheimers Dis
27314527	Early Cognitive Deficits in Type 2 Diabetes: A Population-Based Study. (2016 Jun 15)	Marseglia A	J Alzheimers Dis
29559956	The Role of ApoE Polymorphism in the Relationship between Serum Steroid Hormone Levels and Cognition in Older Chinese Adults: A Cross-Sectional Study. (2018)	Huang X	Front Endocrinol (Lausanne)
28363508	Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence. (2017 Jul)	Hersi M	Neurotoxicology
15258620	Lp(a) and apoE polymorphisms in young South African Indians with myocardial infarction. (2004 May-Jun)	Ranjith N	Cardiovasc J S Afr
15983323	Effect of hepatic lipase -514C->T polymorphism and its interactions with apolipoprotein C3 -482C->T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in chinese type 2 diabetic patients. (2005 Jul)	Baum L	Diabetes Care
17317723	Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. (2007 Jun)	Barbieri SS	FASEB J
26079403	Postmortem Examinations for the Etiological Identification of Juvenile Coronary Arteriosclerosis. (2015 Sep)	Heide S	Am J Forensic Med Pathol
9767914	[Alzheimer disease. Epidemiology, genetics and physiopathological hypotheses]. (1998 Apr 18)	Blain H	Presse Med
16301487	Association of sex steroid hormones with brain morphology and cognition in healthy elderly men. (2005 Nov 22)	Lessov-Schlaggar CN	Neurology
21297261	Socioeconomic status during lifetime and cognitive impairment no-dementia in late life: the population-based aging in the Chianti Area (InCHIANTI) Study. (2011)	Marengoni A	J Alzheimers Dis
11882334	Apolipoprotein E genotype and response of lipid levels to postmenopausal estrogen use. (2002 Mar)	von Muhlen D	Atherosclerosis
15571629	The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee. (2004 Nov 30)	Strandhagen E	Lipids Health Dis
16823865	An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation. (2006 Oct)	Bojanowski CM	Environ Mol Mutagen
21498624	Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. (2011 Jun 15)	McKay GJ	Am J Epidemiol
24346170	Genetic evidence for role of carotenoids in age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS). (2014 Jan 29)	Meyers KJ	Invest Ophthalmol Vis Sci
24825566	Determinants, MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam Study. (2014)	de Bruijn RF	J Alzheimers Dis
21394030	Association of the serum apolipoprotein levels with the occurrence of coronary vasospasm. (2011 May)	Tani S	Coron Artery Dis
17466101	ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. (2007 May)	Minihane AM	Proc Nutr Soc
27834689	Nicotine Accelerates Atherosclerosis in Apolipoprotein E-Deficient Mice by Activating alpha7 Nicotinic Acetylcholine Receptor on Mast Cells. (2017 Jan)	Wang C	Arterioscler Thromb Vasc Biol
17105908	Genes and gene expression in the brains of human alcoholics. (2006 Aug)	Dodd PR	Ann N Y Acad Sci
20031552	Interactions of functional apolipoprotein E gene promoter polymorphisms with smoking on aortic atherosclerosis. (2008 Dec)	Viiri LE	Circ Cardiovasc Genet
10835442	Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. (2000 Jun)	Hirono N	Stroke
20072115	Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers. (2010 Apr)	Marchant NL	Neuropsychopharmacology
22071360	Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. (2012 Feb)	Gustavsson J	Atherosclerosis
20429872	Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study. (2010 Apr 29)	Ariza MJ	BMC Med Genet
20956786	Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. (2010 Oct 19)	Hooshmand B	Neurology
23178747	Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia. (2013 Feb 1)	Lee MJ	Clin Chim Acta
12707449	Comparison of Alzheimer's disease risk factors in white and African American families. (2003 Apr 22)	Bachman DL	Neurology
29021777	Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson's Risk. (2017)	Zhang L	Front Neurol
12006397	Impact of alcohol intake on measures of lipid metabolism depends on context defined by gender, body mass index, cigarette smoking, and apolipoprotein E genotype. (2002 May 1)	Lussier-Cacan S	Arterioscler Thromb Vasc Biol
12006394	Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. (2002 May 1)	Tai ES	Arterioscler Thromb Vasc Biol
27015805	Human longevity is influenced by many genetic variants: evidence from 75,000 UK Biobank participants. (2016 Mar)	Pilling LC	Aging (Albany NY)
10197285	Lipoprotein (a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. (1999 Feb)	Peng DQ	J Cardiovasc Risk
10996872	[Apolipoprotein E gene polymorphism and risk of hypercholesterolemia: a case control study in a working population of Valencia]. (2000 Jul 1)	Corella D	Med Clin (Barc)
26609137	An 8-Month Systems Toxicology Inhalation/Cessation Study in Apoe-/- Mice to Investigate Cardiovascular and Respiratory Exposure Effects of a Candidate Modified Risk Tobacco Product, THS 2.2, Compared With Conventional Cigarettes. (2016 Feb)	Phillips B	Toxicol Sci
24133901	Association between the polymorphism of estrogen receptor alpha and Alzheimer's disease in Chinese population. (2013)	Deng J	Clin Lab
27207171	The Apoe(-/-) mouse model: a suitable model to study cardiovascular and respiratory diseases in the context of cigarette smoke exposure and harm reduction. (2016 May 20)	Lo Sasso G	J Transl Med
28324763	Interaction of APOE e4 and poor glycemic control predicts white matter hyperintensity growth from 73 to 76. (2017 Jun)	Cox SR	Neurobiol Aging
27806189	Effect of the Interplay Between Genetic and Behavioral Risks on Survival After Age 75. (2016 Dec)	Rizzuto D	J Am Geriatr Soc
21791923	Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. (2011)	Ronnemaa E	Dement Geriatr Cogn Disord
26503029	Associations of chronic conditions, APOE4 allele, stress factors, and health behaviors with self-rated health. (2015 Oct 26)	Hu W	BMC Geriatr
24871875	Late-life cynical distrust, risk of incident dementia, and mortality in a population-based cohort. (2014 Jun 17)	Neuvonen E	Neurology
10848855	Apolipoprotein E genotype is associated with differential expansion rates of small abdominal aortic aneurysms. (2000 Jun)	Gerdes LU	Br J Surg
18156097	Gender, a significant factor in the cross talk between genes, environment, and health. (2007)	Ordovas JM	Gend Med
10508208	Association of the A-204C polymorphism in the cholesterol 7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. (1999 Oct)	Couture P	J Lipid Res
10464784	Role of lipid, apolipoprotein levels and apolipoprotein E genotype in young Italian patients with myocardial infarction. (1999 Jun)	Scaglione L	Nutr Metab Cardiovasc Dis
25932792	Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. (2015 Jun)	Savinova OV	Atherosclerosis
28111298	Aerosol from Tobacco Heating System 2.2 has reduced impact on mouse heart gene expression compared with cigarette smoke. (2017 Mar)	Szostak J	Food Chem Toxicol
22752805	Prevalence of myocardial infarction polymorphisms in Afyonkarahisar, Western Turkey. (2012 Sep)	Onrat ST	Mol Biol Rep
27662317	Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging. (2017)	Savica R	J Alzheimers Dis
16266401	The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. (2005 Nov)	Talmud PJ	Ann Hum Genet
10712408	Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles: The Framingham Offspring Study. (2000 Mar)	Couture P	Arterioscler Thromb Vasc Biol
18079687	Apolipoprotein E gene and retinal microvascular signs in older people: the Cardiovascular Health Study. (2007 Nov 12)	Sun C	Mol Vis
12212789	Genetic and environmental risk factors for Alzheimer's disease in Israeli Arabs. (2002 Aug-Oct)	Bowirrat A	J Mol Neurosci
11474482	Environmental factors modulate the effect of the APOE genetic polymorphism on plasma lipid concentrations: ecogenetic studies in a Mediterranean Spanish population. (2001 Aug)	Corella D	Metabolism
17273655	Relevance of apolipoprotein E4 for the lipid profile of Brazilian patients with coronary artery disease. (2007 Feb)	Souza DR	Braz J Med Biol Res
23731952	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. (2013 Nov)	Benedictus MR	Neurobiol Aging
22460205	Genetic variants at the APOE, lipoprotein lipase (LpL), cholesteryl ester transfer protein (CETP), and endothelial nitric oxide (eNOS) genes and coronary artery disease (CAD): CETP Taq1 B2B2 associates with lower risk of CAD in Asian Indians. (2010 Jun)	Bhanushali AA	J Community Genet
11893778	Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus. (2002 Mar)	Corella D	J Lipid Res
18318693	Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. (2008 Dec)	Kivipelto M	J Cell Mol Med
15585780	Apolipoprotein E polymorphism modifies the alcohol-HDL association observed in the National Heart, Lung, and Blood Institute Family Heart Study. (2004 Dec)	Djousse L	Am J Clin Nutr
14646029	Apolipoprotein E and mortality in African-Americans and Yoruba. (2003 Oct)	Lane KA	J Alzheimers Dis
27236033	LDLR, ApoB and ApoE genes polymorphisms and classical risk factors in premature coronary artery disease. (2016 Sep 30)	Abd El-Aziz TA	Gene
21267519	Omega-3 polyunsaturated fatty acid supplements and cognitive decline: Singapore Longitudinal Aging Studies. (2011 Jan)	Gao Q	J Nutr Health Aging
16030523	Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. (2005 Oct)	van Aalst-Cohen ES	Eur J Hum Genet
29030599	Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. (2017 Oct 13)	Joshi PK	Nat Commun
20739649	Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. (2010 Aug 31)	Matsuzaki T	Neurology
26280289	Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-epsilon3/epsilon3 Patients With Late-onset Alzheimer Disease Dementia. (2015 Aug)	Oliveira FF	Neurologist
26322175	Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. (2015 Aug 26)	Husain K	World J Biol Chem
28128572	[Genetic determination of dyslipidemia - What tell us the results of genome-wide association studies?] (Fall 2016)	Hubacek JA	Vnitr Lek
17460252	The association between retinal vascular network geometry and cognitive ability in an elderly population. (2007 May)	Patton N	Invest Ophthalmol Vis Sci
21813245	AMPK gamma2 subunit gene PRKAG2 polymorphism associated with cognitive impairment as well as diabetes in old age. (2012 Mar)	Kim E	Psychoneuroendocrinology
25048271	Influence of lifestyle modifications on age-related free radical injury to brain. (2014 Sep)	Peskind ER	JAMA Neurol
17356695	Variation in GYS1 interacts with exercise and gender to predict cardiovascular mortality. (2007 Mar 14)	Fredriksson J	PLoS One
24709049	Retrospective lifetime dietary patterns predict cognitive performance in community-dwelling older Australians. (2014 Jul 28)	Hosking DE	Br J Nutr
12011802	The interaction of serum folate and estradiol levels in Alzheimer's disease. (2002 Apr)	Hogervorst E	Neuro Endocrinol Lett
9760210	An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E. (1998 Aug)	Stengard JH	Hum Genet
25173947	A systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease. (2014 Nov)	Holmes MV	Atherosclerosis
27027324	Effects of cigarette smoke, cessation and switching to a candidate modified risk tobacco product on the liver in Apoe -/- mice--a systems toxicology analysis. (2016 Apr)	Lo Sasso G	Inhal Toxicol
16401842	Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. (2006 Jan 10)	Rippon GA	Neurology
23382465	Smoking, apolipoprotein E genotypes, and mortality (the Ludwigshafen RIsk and Cardiovascular Health study). (2013 May)	Grammer TB	Eur Heart J
22328704	Apolipoprotein E gene associations in age-related macular degeneration: the Melbourne Collaborative Cohort Study. (2012 Mar 15)	Adams MK	Am J Epidemiol
25730733	Blood pressure interacts with APOE epsilon4 to predict memory performance in a midlife sample. (2015 Sep)	Oberlin LE	Neuropsychology
16288198	Joint effects of smoking history and APOE genotypes in age-related macular degeneration. (2005 Nov 4)	Schmidt S	Mol Vis
20198932	Normal cognitive decline or dementia? (2010 Jan)	Ebmeier KP	Practitioner
21108621	The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. (2011 Feb)	Molchadski I	Acta Neurol Scand
21919778	Correlation between common genetic variants and risk factors associated with prediction of cardiovascular diseases in dyslipidemic patients. (2012 Mar)	Kotaska K	Genet Test Mol Biomarkers
9409302	Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. (1997 Nov)	Vuorio AF	Arterioscler Thromb Vasc Biol
28783817	Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. (2017 Oct 1)	Gottesman RF	JAMA Neurol
10217374	Influence of apolipoprotein E polymorphism on serum lipids and lipoprotein changes from childhood to adulthood: the Bogalusa Heart Study. (1999 Apr)	Srinivasan SR	Atherosclerosis
11580913	Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level. (2001 Oct)	Sakurabayashi I	Clin Chim Acta
16186526	Effect of smoking and time on cognitive function in the elderly without dementia. (2005 Sep 27)	Reitz C	Neurology
25707516	Frequencies of apolipoprotein E alleles in depressed patients undergoing hemodialysis--a case-control study. (2015 Jun)	Su YY	Ren Fail
28889112	Interplay between cigarette smoking and pulmonary reverse lipid transport. (2017 Sep)	Jubinville E	Eur Respir J
1947727	Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease. (1991 Sep)	Stuyt PM	Scand J Clin Lab Invest
22405042	Determinants of cerebellar and cerebral volume in the general elderly population. (2012 Dec)	Hoogendam YY	Neurobiol Aging
17901562	Potentially reduced exposure cigarettes accelerate atherosclerosis: evidence for the role of nicotine. (2007)	Catanzaro DF	Cardiovasc Toxicol
24014251	Adjustment for smoking does not alter the FOXO3A association with longevity. (2014 Apr)	Daumer C	Age (Dordr)
15879922	Polymorphisms associated with thrombophilia and vascular homeostasis and the timing of menarche and menopause in 728 white women. (2005 May-Jun)	Tempfer CB	Menopause
11730822	Association of the A/T54 polymorphism in the intestinal fatty acid binding protein with variations in plasma lipids in the Framingham Offspring Study. (2001 Dec)	Galluzzi JR	Atherosclerosis
28167353	Genetic risk analysis of coronary artery disease in Pakistani subjects using a genetic risk score of 21 variants. (2017 Mar)	Shahid SU	Atherosclerosis
11273848	Alcohol drinking determines the effect of the APOE locus on LDL-cholesterol concentrations in men: the Framingham Offspring Study. (2001 Apr)	Corella D	Am J Clin Nutr
15229130	The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. (2004 Sep)	Singhal S	Brain
19506566	Overweight in midlife and risk of dementia: a 40-year follow-up study. (2009 Aug)	Hassing LB	Int J Obes (Lond)
25709077	EFFECT OF THE APOE epsilon4 ALLELE AND COMBAT EXPOSURE ON PTSD AMONG IRAQ/AFGHANISTAN-ERA VETERANS. (2015 May)	Kimbrel NA	Depress Anxiety
18057788	[Oxidative stress and atherosclerosis]. (2007 Dec)	Kunitomo M	Yakugaku Zasshi
10886490	Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: the Berlin ageing study. (2000 Jun)	Hillen T	J Intern Med
12766793	Plasma total homocysteine levels, dietary vitamin B6 and folate intake in AD and healthy aging. (2003)	Mizrahi EH	J Nutr Health Aging
24096154	Cigarette smoke induces molecular responses in respiratory tissues of ApoE(-/-) mice that are progressively deactivated upon cessation. (2013 Dec 6)	Boue S	Toxicology
22561688	Activation of AMP-activated protein kinase alpha2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo. (2012 Jun)	Wang S	Nat Med
19750560	The effect of alcohol and tobacco consumption, and apolipoprotein E genotype, on the age of onset in Alzheimer's disease. (2010 May)	Harwood DG	Int J Geriatr Psychiatry
20451958	Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette smoke is attenuated by P2Y12 antagonism. (2010 Oct)	Dong A	Thromb Res
10668701	The association between APOE and dementia does not seem to be mediated by vascular factors. (2000 Jan 25)	Prince M	Neurology
25090243	Effect of leukocyte telomere length on total and regional brain volumes in a large population-based cohort. (2014 Oct)	King KS	JAMA Neurol
17580963	Modification by acrolein, a component of tobacco smoke and age-related oxidative stress, mediates functional impairment of human apolipoprotein E. (2007 Jul 17)	Tamamizu-Kato S	Biochemistry
27222041	A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics. (2016 Aug 11)	Poersch A	J Proteomics
14612205	APOE polymorphism and lipid profile in three ethnic groups in the Singapore population. (2003 Oct)	Tan CE	Atherosclerosis
29215900	APOE e4-genotype and lifestyle interaction on cognitive performance: Results of the LIFE-Adult-study. (2018 Feb)	Rodriguez FS	Health Psychol
28269770	Psychosocial Risk and Protective Factors and Incident Mild Cognitive Impairment and Dementia in Community Dwelling Elderly: Findings from the Singapore Longitudinal Ageing Study. (2017)	Rawtaer I	J Alzheimers Dis
19157170	Combined "pro-atherosclerotic" variants of the ACE and APOE genes increase the risk of the coronary artery disease associated with the presence of cigarette smoking. (2008 Dec)	Zak I	Acta Cardiol
18401020	Impaired insulin secretion increases the risk of Alzheimer disease. (2008 Sep 30)	Ronnemaa E	Neurology
23021038	Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention. (2013 Jan)	Vanitallie TB	Metabolism
8655152	Genotypes with the apolipoprotein epsilon4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men. (1996 May)	Stengard JH	Hum Genet
18210157	Exploring gene-environment interactions in Parkinson's disease. (2008 Apr)	McCulloch CC	Hum Genet
20117127	Low level of the mtDNA(4977) deletion in blood of exceptionally old individuals. (2010 Mar)	von Wurmb-Schwark N	Mech Ageing Dev
9878681	Ionizing radiation and genetic risks. VI. Chronic multifactorial diseases: a review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus. (1999 Jan)	Sankaranarayanan K	Mutat Res
18515697	Metabolic syndrome and cognitive decline in chinese older adults: results from the singapore longitudinal ageing studies. (2008 Jun)	Ho RC	Am J Geriatr Psychiatry
17130180	Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. (2007 Jan)	Humphries SE	Clin Chem
10025785	CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. (1999 Feb)	Samuels SC	Neurology
10025786	A cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics. (1999 Feb)	Harwood DG	Neurology
9652667	Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. (1998 Jun 20)	Ott A	Lancet
27770636	Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. (2017 Feb)	Mez J	Alzheimers Dement
15793777	[The apolipoprotein E-CI-CII gene cluster polymorphisms and coronary artery disease]. (2005 Apr)	Wang C	Zhonghua Yi Xue Yi Chuan Xue Za Zhi
15488872	No APOEepsilon4 effect on coronary heart disease risk in a cohort with low smoking prevalence: the Whitehall II study. (2004 Nov)	Talmud PJ	Atherosclerosis
23490293	Low-density lipoprotein receptor-related protein 5 gene polymorphisms and genetic susceptibility to abdominal aortic aneurysm. (2013 Oct)	Galora S	J Vasc Surg
10420064	Risk factors for vascular disease and dementia. (1998 May-Aug)	Breteler MM	Haemostasis
8886322	Genetic variation and nutrition. (1996 Sep)	Simopoulos AP	Biomed Environ Sci
26380972	Selenium Level and Dyslipidemia in Rural Elderly Chinese. (2015)	Su L	PLoS One
28457809	Circulating inflammatory biomarkers in relation to brain structural measurements in a non-demented elderly population. (2017 Oct)	Gu Y	Brain Behav Immun
23899991	Homocysteine levels and dementia risk in Yoruba and African Americans. (2013 Nov)	Hendrie HC	Int Psychogeriatr
29509901	Apolipoprotein E DNA methylation and late-life disease. (2018 Mar 2)	Karlsson IK	Int J Epidemiol
11463413	Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. (2001 Jul 14)	Humphries SE	Lancet
21841254	Gender differences in tea, coffee, and cognitive decline in the elderly: the Cardiovascular Health Study. (2011)	Arab L	J Alzheimers Dis
15767859	The genetics of stroke. (2005 Apr)	Morgan L	Curr Opin Lipidol
18663180	Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. (2008 Jul 29)	Cramer C	Neurology
21741729	Apolipoprotein E genotypes and the risk of Parkinson disease. (2011 Nov)	Gao J	Neurobiol Aging
29117962	Lower cardiac index levels relate to lower cerebral blood flow in older adults. (2017 Dec 5)	Jefferson AL	Neurology
29532745	Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis. (2018 Mar 1)	Graetz C	Mult Scler
23731637	Cardiovascular risk profile in patients with spondyloarthritis. (2014 Jan)	Papagoras C	Joint Bone Spine
19054180	Albumin, apolipoprotein E-epsilon4 and cognitive decline in community-dwelling Chinese older adults. (2009 Jan)	Ng TP	J Am Geriatr Soc
25024309	The prevalence of age-related macular degeneration in Alzheimer's disease. (2014)	Williams MA	J Alzheimers Dis
28418521	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. (2017 Jun 1)	Vemuri P	JAMA Neurol
19473356	Apolipoprotein E polymorphism interacts with cigarette smoking in progression of multiple sclerosis. (2009 Jul)	Sena A	Eur J Neurol
15060087	The lipoprotein lipase S447X polymorphism and plasma lipids: interactions with APOE polymorphisms, smoking, and alcohol consumption. (2004 Jun)	Lee J	J Lipid Res
17367769	Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes. (2007 May 1)	Fiegenbaum M	Clin Chim Acta
28199971	Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population. (2017 Apr 11)	Lin E	Oncotarget
22003152	Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. (2012 Jan)	Grallert H	Eur Heart J
26398858	Association of Apolipoprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration. (2016 Jun)	Bakbak B	Curr Eye Res
23748423	Nicotine potentiates proatherogenic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling. (2013 Aug 15)	Zhou MS	Am J Physiol Heart Circ Physiol
12739024	Apolipoprotein e4 allele and endothelium-dependent arterial dilation in Type 2 diabetes mellitus without angiopathy. (2003 Apr)	Guangda X	Diabetologia
16426594	The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European population. (2006 Apr)	Sorli JV	Clin Chim Acta
11164125	Independent and interactive effects of apolipoprotein E phenotype and cardiorespiratory fitness on plasma lipids. (2001 Feb)	Schmitz KH	Ann Epidemiol
29132311	Weighted gene co-expression network analysis of expression data of monozygotic twins identifies specific modules and hub genes related to BMI. (2017 Nov 13)	Wang W	BMC Genomics
11423496	Association of the Ala54-Thr polymorphism in the intestinal fatty acid-binding protein with 2-h postchallenge insulin levels in the Framingham Offspring Study. (2001 Jul)	Galluzzi JR	Diabetes Care
9684753	Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities. (1998 Jul)	Mero N	J Lipid Res
29661060	Mental Work Demands and Late-Life Cognitive Impairment: Results From the Shanghai Aging Study. (2018 Apr 1)	Liang X	J Aging Health
24305621	C-reactive protein, APOE genotype and longitudinal cognitive change in an older population. (2014 Mar)	Lima TA	Age Ageing
23892702	Risk factors for dementia with Lewy bodies: a case-control study. (2013 Aug 27)	Boot BP	Neurology
20442857	Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. (2010 Apr 29)	Suchindran S	PLoS Genet
25426275	Association between Apolipoprotein E Polymorphism and Chronic Kidney Disease in the Korean General Population: Dong-gu Study. (2014 Nov)	Choi SW	Korean J Fam Med
16766085	GABA(A) receptor beta isoform protein expression in human alcoholic brain: interaction with genotype. (2006 Nov)	Buckley ST	Neurochem Int
19494429	Alcohol drinking, cognitive functions in older age, predementia, and dementia syndromes. (2009)	Panza F	J Alzheimers Dis
21912625	An exploratory study on CLU, CR1 and PICALM and Parkinson disease. (2011)	Gao J	PLoS One
15824373	Smoking affects the phenotype of Alzheimer disease. (2005 Apr 12)	Sabbagh MN	Neurology
8841324	Apolipoprotein E polymorphism is associated with segment-specific extracranial carotid artery intima-media thickening. (1996 Oct)	Terry JG	Stroke
17721898	Work-related physical activity and the risk of dementia and Alzheimer's disease. (2007 Sep)	Rovio S	Int J Geriatr Psychiatry
21245181	Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. (2011 Jan 19)	Yaffe K	JAMA
22520940	Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. (2012 Apr 23)	Chaudhary R	Cardiovasc Diabetol
15039035	Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. (2004 Apr)	Humphries SE	Lancet Neurol
27869301	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. (2017 Apr)	Wennberg AMV	J Am Geriatr Soc
23808899	APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset. (2013 Jul)	Kalapatapu RK	Am J Drug Alcohol Abuse
21882290	Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. (2011 Dec)	McKay GJ	Hum Mutat
9929680	Apolipoprotein E status is associated with odor identification deficits in nondemented older persons. (1998 Nov 30)	Murphy C	Ann N Y Acad Sci
20524007	Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta. (2010 Oct)	Sena A	J Neurol
24456740	Apolipoprotein E polymorphism is associated with lower extremity deep venous thrombosis: color-flow Doppler ultrasound evaluation. (2014 Jan 24)	Zhu S	Lipids Health Dis
10662806	Genetic susceptibility to age related macular degeneration. (2000 Feb)	Yates JR	J Med Genet
10232045	Nitric oxide and platelet aggregation. (1999)	Riddell DR	Vitam Horm
29096742	HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy. (2017 Oct 31)	Kirac D	Cell Mol Biol (Noisy-le-grand)
25085446	No change of the lipid profile under the control of ApoE gene polymorphism in schizophrenics under paliperidone treatment. (2014 Dec)	Kao WT	Psychiatr Q
17683517	The Mediterranean paradox for susceptibility factors in coronary heart disease extends to genetics. (2008 Jan)	Lao O	Ann Hum Genet
19720080	Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review. (2010 Mar)	Low LF	Neurosci Biobehav Rev
26058877	Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung. (2015 Sep)	Rice SJ	Proteomics
10202267	The effect of apolipoprotein E epsilon4 in the relationships of smoking and drinking to cognitive function. (1999)	Carmelli D	Neuroepidemiology
23741513	Association of cardiovascular burden with mobility limitation among elderly people: a population-based study. (2013)	Welmer AK	PLoS One
18203129	Impact of apoE genotype on oxidative stress, inflammation and disease risk. (2008 Jan)	Jofre-Monseny L	Mol Nutr Food Res
12573381	Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E epsilon2/epsilon3/epsilon4 genotype. (2003 Feb 1)	Keavney B	Lancet
19667307	APOE genotype, lipids, and coronary heart disease risk: a prospective population study. (2009 Aug 10)	Ward H	Arch Intern Med
12742802	Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. (2003 May 12)	Tan ZS	Arch Intern Med
12658367	Apolipoprotein E epsilon 4 is associated with hippocampal volume reduction in females with alcoholism. (2003 Apr)	Bleich S	J Neural Transm (Vienna)
12579507	[Apolipoprotein E genotypes and carotid artery atherosclerosis in type 2 diabetes mellitus]. (2003 Feb)	Xiang GD	Zhonghua Yi Xue Yi Chuan Xue Za Zhi
16116614	Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. (2006 Jan)	Pankratz N	Mov Disord
25268647	The apolipoprotein E polymorphism rs7412 associates with body fatness independently of plasma lipids in middle aged men. (2014)	Tejedor MT	PLoS One
25449275	Varenicline aggravates plaque formation through alpha7 nicotinic acetylcholine receptors in ApoE KO mice. (2014 Dec 12)	Koga M	Biochem Biophys Res Commun
10931797	Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. (2000 Aug 8)	Matetzky S	Circulation
24772377	Apolipoprotein Gene Polymorphisms (APOB, APOC111, APOE) in the Development of Coronary Heart Disease in Ethnic Groups of Kazakhstan. (2014 Jan 24)	Berkinbayev S	J Genet Syndr Gene Ther
26670299	Genetic risk factors for spontaneous intracerebral haemorrhage. (2016 Jan)	Carpenter AM	Nat Rev Neurol
15374172	Apolipoprotein E epsilon4 allele, skin vessel reactivity and vascular risk factors in Alzheimer's disease. (1996 May-Jun)	Algotsson A	Arch Gerontol Geriatr
15111581	Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center. (2004 May)	Zareparsi S	Invest Ophthalmol Vis Sci
24471738	Apolipoprotein E polymorphisms and ischaemic stroke: a two-center Greek study. (2014 Aug)	Chatzistefanidis D	Eur J Neurol
23797033	Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. (2013 Dec)	D'Amico E	Free Radic Biol Med
15070435	How to identify gene-environment interactions in a multifactorial disease: CHD as an example. (2004 Feb)	Talmud PJ	Proc Nutr Soc
29642385	MicroRNAs as Potential Mediators for Cigarette Smoking Induced Atherosclerosis. (2018 Apr 6)	Yokoyama Y	Int J Mol Sci
16459141	Combined effects of apoE-CI-CII cluster and LDL-R gene polymorphisms on chromosome 19 and coronary artery disease risk. (2006 May)	Wang C	Int J Hyg Environ Health
17420762	Apolipoprotein E polymorphism, homocysteine serum levels and hippocampal volume in patients with alcoholism: an investigation of a gene-environment interaction. (2008 Apr)	Wilhelm J	Pharmacogenomics J
19187685	[Influence of the APOE genotypes in some atherosclerotic risk factors]. (2008 Sep-Oct)	Carmo Martins M	Acta Med Port
15155954	Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. (2004 Aug)	Jeerakathil T	Stroke
22933840	Association analysis of genetic and environmental risk factors in the cuticular drusen subtype of age-related macular degeneration. (2012)	van de Ven JP	Mol Vis
22111029	Premature coronary artery disease and familial hypercholesterolemia: need for early diagnosis and cascade screening in the Indian population. (2012)	Setia N	Cardiol Res Pract
11058709	Apolipoprotein E polymorphism and carotid artery intima-media thickness in a random sample of middle-aged men. (2000 Nov)	Ilveskoski E	Atherosclerosis
29416034	Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. (2018 Feb 7)	Wu X	Cell Death Dis
18591462	Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. (2008 Aug)	Singh-Manoux A	Arterioscler Thromb Vasc Biol
20876472	A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. (2010 Sep 28)	Kay DM	Neurology
19273753	Contribution of vascular risk factors to the progression in Alzheimer disease. (2009 Mar)	Helzner EP	Arch Neurol
25672924	Effects of vascular risk factors and APOE epsilon4 on white matter integrity and cognitive decline. (2015 Mar 17)	Wang R	Neurology
15186941	Aberrant antibody responses to oxidized LDL and increased intimal thickening in apoE-/- mice exposed to cigarette smoke. (2004 Jul)	Tani S	Atherosclerosis
15953853	The effect of apolipoprotein E polymorphism on lipid levels in Korean adults. (2005 Jun)	Shin MH	J Korean Med Sci
10354721	[Cognitive impairment and cardiovascular disease risk factors. Project CASCADE Krakow. I. Project to test exposure to risk factors for cardiovascular disease in the studied sample]. (1998)	Pajak A	Przegl Lek
27249957	CHRNA7 Polymorphisms and Dementia Risk: Interactions with Apolipoprotein epsilon4 and Cigarette Smoking. (2016 Jun 2)	Weng PH	Sci Rep
15673344	Relationship between plasma lipids and all-cause mortality in nondemented elderly. (2005 Feb)	Schupf N	J Am Geriatr Soc
11714857	Genetic influences on lipid metabolism trait variability within the Stanislas Cohort. (2001 Nov)	Pallaud C	J Lipid Res
25194823	Assessment of sleep satisfaction in patients with dementia due to Alzheimer's disease. (2014 Dec)	de Oliveira FF	J Clin Neurosci
28304310	Smoking, APOE Genotype, and Cognitive Decline: The Rotterdam Study. (2017)	Wingbermuhle R	J Alzheimers Dis
26890557	Maternal apolipoprotein E genotype as a potential risk factor for poor birth outcomes: The Bogalusa Heart Study. (2016 Jun)	Jacobs MB	J Perinatol
12473860	Apolipoprotein E polymorphism affects carotid artery atherosclerosis in smoking hypertensive men. (2002 Dec)	Karvonen J	J Hypertens
11323547	Physical activity and cognitive decline, the role of the apolipoprotein e4 allele. (2001 May)	Schuit AJ	Med Sci Sports Exerc
26121922	Cumulative lead exposure is associated with reduced olfactory recognition performance in elderly men: The Normative Aging Study. (2015 Jul)	Grashow R	Neurotoxicology
17846408	Mediterranean diet and Alzheimer disease mortality. (2007 Sep 11)	Scarmeas N	Neurology
20803190	Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort. (2011 Feb)	Jacobson AM	Diabetologia
17950492	Sex differences in the causes and consequences of white matter hyperintensities. (2009 Jun)	Sachdev PS	Neurobiol Aging
18703981	Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. (2009 Jan-Mar)	Purnell C	Alzheimer Dis Assoc Disord
20682755	A pilot study of gene/gene and gene/environment interactions in Alzheimer disease. (2011 Mar)	Ghebranious N	Clin Med Res
29091778	Risk factors for amyloid positivity in older people reporting significant memory concern. (2018 Jan)	Zhang J	Compr Psychiatry
22951857	Dysfunction of high-density lipoprotein and its apolipoproteins: new mechanisms underlying cardiometabolic risk in the population at large. (2012 Jun)	Onat A	Turk Kardiyol Dern Ars
12714116	Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. (2003 Jul-Aug)	Tyas SL	Neurobiol Aging
8890771	Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease. (1996 Oct)	Whitehead AS	J Neurol Neurosurg Psychiatry
24950858	Stroke incidence and risk factors in Havana and Matanzas, Cuba. (2015 Oct)	Llibre-Guerra JC	Neurologia
23324992	Interactive effects of ApoE polymorphism, alcohol and smoking on age-related trends of blood pressure levels in elderly men: the Bambui Cohort Study of Ageing (1997-2008). (2013 Aug)	Leite ML	J Hum Hypertens
15144588	[Interaction of ApoE and LDL-R gene polymorphisms and alcohol drinking and smoking on coronary heart disease]. (2004 Apr 2)	Wang CH	Zhonghua Yi Xue Za Zhi
29745686	Does incipient dementia explain normal cognitive decline determinants? Lothian birth cohort 1921. (2018 May 10)	Sibbett RA	Psychol Aging
12580704	Antioxidant vitamin intake and risk of Alzheimer disease. (2003 Feb)	Luchsinger JA	Arch Neurol
8218104	Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. (1993 Nov)	Amouyel P	Arterioscler Thromb
27574384	Genetic Polymorphisms Influence Cognition in Patients Undergoing Carotid Interventions. (2016 Sep)	Hitchner E	Int J Angiol
23247396	APOE varepsilon4, an Alzheimer's disease susceptibility allele, and smoking cessation. (2013 Dec)	Ashare RL	Pharmacogenomics J
24944262	APOE polymorphisms and cognitive functions in patients with brain tumors. (2014 Jul 22)	Correa DD	Neurology
18990452	Serum cholesterol, apolipoprotein E genotype and depressive symptoms in elderly European men: the FINE study. (2009 Jun)	Giltay EJ	J Affect Disord
21447678	Association of variants in the LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration. (2011 Jun 28)	Yu Y	Invest Ophthalmol Vis Sci
22206590	The relationship between apolipoprotein (apo) E polymorphism and lipid changes: An 8-year cohort study in Beijing elderly persons. (2012 Nov-Dec)	Guan S	Arch Gerontol Geriatr
12379174	Genetics, the environment, and lipid abnormalities. (2002 Nov)	Ordovas JM	Curr Cardiol Rep
11815309	Lipoproteins, nutrition, and heart disease. (2002 Feb)	Schaefer EJ	Am J Clin Nutr
16519597	Associations of apolipoprotein E exon 4 and lipoprotein lipase S447X polymorphisms with acute ischemic stroke and myocardial infarction. (2006)	Baum L	Clin Chem Lab Med
17177184	Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. (2007 Feb 15)	Huang X	Mov Disord
24596166	Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from Sao Paulo, Brazil. (2014 Oct)	de Oliveira FF	Int J Geriatr Psychiatry
15809232	Polymorphisms of apolipoprotein E and angiotensin-converting enzyme genes and carotid atherosclerosis in heavy drinkers. (2005 Jul-Aug)	Bednarska-Makaruk M	Alcohol Alcohol
26574747	Demographic and Lifestyle Characteristics, but Not Apolipoprotein E Genotype, Are Associated with Intelligence among Young Chinese College Students. (2015)	Chen XF	PLoS One
20548041	Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. (2010 Jun 15)	Goos JD	Neurology
12534843	Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures. (2003 Jan)	Lui LY	J Am Geriatr Soc
7583549	Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. (1995 Oct)	Miserez AR	Arterioscler Thromb Vasc Biol
18324906	Association of high sensitive C-reactive protein with apolipoprotein E polymorphism in children and young adults: the Cardiovascular Risk in Young Finns Study. (2008)	Gronroos P	Clin Chem Lab Med
15942426	Smoking, apolipoprotein E genotype, and early onset of coronary heart disease. (2005 Jun)	Loew M	Eur J Cardiovasc Prev Rehabil
21276236	Dietary intake in the Personalized Medicine Research Project: a resource for studies of gene-diet interaction. (2011 Jan 28)	Strobush L	Nutr J
16028714	Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. (2005 Apr)	Dietrich M	Lipids
23664439	Association between levels of serum perfluorooctane sulfate and carotid artery intima-media thickness in adolescents and young adults. (2013 Oct 9)	Lin CY	Int J Cardiol
24789331	Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. (2014 Dec)	Ahles TA	Psychooncology
17426996	Apolipoprotein E epsilon4 genotype is independently associated with increased intima-media thickness in a recessive pattern. (2007 May)	Wohlin M	Lipids
15469403	Pharmacogenomics and drug response in cardiovascular disorders. (2004 Oct)	Siest G	Pharmacogenomics
12535745	A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. (2003 Feb)	Liu S	Atherosclerosis
15911795	Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. (2005 May 24)	Enzinger C	Neurology
17141963	Apolipoprotein E epsilon4 offers protection against age-related macular degeneration. (2007)	Friedman DA	Med Hypotheses
16951484	ApoE polymorphism is associated with C-reactive protein in low-HDL family members and in normolipidemic subjects. (2006)	Kahri J	Mediators Inflamm
10686532	Relationship of family history scores for stroke and hypertension to quantitative measures of white-matter hyperintensities and stroke volume in elderly males. (2000 Mar-Apr)	Reed T	Neuroepidemiology
25730003	Association of the ApoE gene polymorphism and dietary factors with cerebral infarction and circulating lipid concentrations. (2015 Jan 30)	Yan HQ	Genet Mol Res
27164694	APOE epsilon4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. (2016 May 31)	van de Rest O	Neurology
21557673	Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. (2011)	Hubacek JA	Drug Metabol Drug Interact
16713503	Apolipoprotein E4 genotype is not associated with short-term cognition deficits during alcohol withdrawal. (2005 Nov)	Wilhelm J	Alcohol
25847292	Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. (2016 Feb)	Durazzo TC	Nicotine Tob Res
16406547	Apolipoprotein E gene and early age-related maculopathy: the Atherosclerosis Risk in Communities Study. (2006 Feb)	Wong TY	Ophthalmology
23840704	Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. (2013)	Geng L	PLoS One
22347399	Preliminary evidence for an association between LRP-1 genotype and body mass index in humans. (2012)	Frazier-Wood AC	PLoS One
20515477	Effect of Apolipoprotein E epsilon4 on the association between health behaviors and cognitive function in late midlife. (2010 Jun 1)	Sabia S	Mol Neurodegener
10534255	Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon4 status. (1999 Oct 22)	Graves AB	Neurology
23299282	Risk factors for dementia with type 2 diabetes mellitus among elderly people in China. (2013 May)	Fei M	Age Ageing
11739991	Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. (2001 Dec 1)	Peila R	Stroke
17420320	Relation of diabetes to mild cognitive impairment. (2007 Apr)	Luchsinger JA	Arch Neurol
21432258	Genetic and environmental factors affecting peak bone mass in premenopausal Japanese women. (2001 Oct)	Hayakawa Y	Environ Health Prev Med
16606866	APOE alleles are not associated with calcific aortic stenosis. (2006 Oct)	Ortlepp JR	Heart
21228733	Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. (2011 Mar)	Shahin MH	Pharmacogenet Genomics
16959267	Apolipoprotein E gene polymorphism and previous alcohol withdrawal seizures. (2007 Nov)	Wilhelm J	J Psychiatr Res
11553047	Apolipoprotein E polymorphism and lipid levels differ by gender and family history of diabetes: the Rancho Bernardo Study. (2001 Aug)	Oh JY	Clin Genet